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A B S T R A C T
Current asthma guidelines recommend a control-based approach to management involving assessment of
impairment and risk followed by implementation of treatment strategies individualized according to the pa-
tient’s needs and preferences. However, for children with asthma, achieving control can be elusive. Although
tools are available to help children (and families) track and manage day-to-day symptoms, when and how
to implement a longer-term step-up in care is less clear. Furthermore, treatment is challenged by the 3 age
groups of childhood—adolescence (12–18 years old), school age (6–11 years old), and young children (≤5
years old)—and what works for 1 age group might not be the best approach for another. The Pediatric Asthma
Yardstick provides an in-depth assessment of when and how to step-up therapy for the child with not well
or poorly controlled asthma. Development of this tool follows others in the Yardstick series, presenting patient
proﬁles and step-up strategies based on current guidance documents, but modiﬁed according to newer data
and the authors’ combined clinical experience. The objective is to provide clinicians who treat children with
asthma practical and clinically relevant recommendations for each step-up and each intervention, with the
intent of helping practitioners better treat their pediatric patients with asthma, particularly those who do
not always respond to recommended therapies.
© 2018 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Introduction
The Adult Asthma Yardstick, published in 2017, is a practical, yet
comprehensive, update on how to conduct a sustained step-up in
asthma therapy for the adult patient (≥18 years of age) with inad-
equately controlled asthma.1 Developed with asthma experts as an
adjunct to guidelines and global strategies for the management of
adults with asthma,2,3 it provides a tool to help clinicians proactively
address the loss of asthma control at all levels of severity. The content
excluded children because they present special challenges in man-
aging uncontrolled disease.
Asthma is one of the most common chronic diseases of child-
hood. The Centers for Disease Control and Prevention reported the
overall prevalence of pediatric asthma in the United States in 2015
as 8.4% and among school-age children (6–19 years old) as approx-
imately 10%.4,5 For children, asthma is a primary cause of missed
activities, including school2,5–8; it also is a cause of missed activi-
ties, including work, for their parents and caregivers.7,9 Of long-
term concern is that asthma can be associated with ﬁxed airﬂow
obstruction later in life. Approximately 75% of children with asthma
have abnormal lung growth patterns.10 Those with severe disease
often show chronic airﬂow limitation—deﬁned by a ratio of forced
expiratory volume in 1 second (FEV1) to forced vital capacity lower
than normal11—which, when identiﬁed at school age, commonly per-
sists through adolescence and into adulthood.12–14 Although age-
dependent changes in respiratory system physiology are normal,
in children with asthma, particularly those with severe disease, the
impairment in lung function can affect assessment and response
to therapy.10–26 No current therapy, including inhaled corticoste-
roids (ICSs), leukotriene modiﬁers, or limited data with biological
agents, has been shown to prevent or interrupt the enhanced age-
dependent decline in FEV1 that is a feature of childhood asthma.
A full discussion of lung development in the child with asthma is
beyond the scope of this article, but some changes in respiratory
physiology that might affect response to treatment are presented
in Table 1 and described in greater detail in eCommentary 1.
Although many children with asthma achieve symptom control
with appropriate management, a substantial subset does not. From
2006 to 2010, more than 38% of children with current asthma
had uncontrolled disease.5,27 These children should undergo a
step-up in care, but when and how to do that is not always
straightforward.8,27–29 The Pediatric Asthma Yardstick is a practical
resource for starting or adjusting controller therapy based on the
options that are currently available for children, from infants to 18
years of age. The recommendations, presented in Figure 1, are based
on the therapeutic utility of current step-based strategies (Fig 2)2,3
and presented around patient proﬁles, with commentary accord-
ing to contemporary data and the authors’ clinical experience.
Asthma control is deﬁned according to the frequency and in-
tensity of symptoms, functional limitations, and potential negative
effects of treatment1–3,5 (eTable 1). Left uncontrolled, asthma can
have a signiﬁcant cost to families and society.5,27 Children with un-
controlled asthma are at increased risk for adverse events and
morbidity, including life-threatening exacerbations and associ-
ated hospitalizations, emergency department (ED) visits, and urgent
care visits, which signiﬁcantly increase the economic burden.2,5,8,29,30
Estimates indicate that children with poorly controlled asthma have
double the annual costs for their disease compared with children
with well-controlled asthma.31 Children diagnosed with severe
asthma, approximately 5% of pediatric patients with asthma, account
for 50% of health care system costs related to the disease.28
Current strategies for managing asthma are based on the im-
pairment and risk model (presented in eTable 1), with treatment
guided by severity1–3 (Fig 2). Different medications are included in
each step to allow for individualizing treatment, although the choices
are not necessarily of equal eﬃcacy; preferred therapies are noted.
The goals of management are 2-fold:
• To achieve good control of symptoms, which includes little or
(ideally) no sleep disturbances from asthma and maintaining
normal activity levels; and
Table 1
Age-Dependent Factors in Respiratory Physiology That Can Affect Evaluation and Treatment of the Child With Asthma
Physiologic factor Effect of age Impact
Expired time-volume relations measured by
spirometry10–12,15,16
FEV1 increases up to young adulthood and then decreases 75% of children with asthma have abnormal decline
patterns with age; at risk for persistent airﬂow limitation
and COPD
FVC decreases after young adulthood from decreased muscle
strength and loss of tissue-supporting structures
can be low in asthma from increased secretions and mucus
plugs
FEV1/FVC pre-bronchodilator stable with age, whereas post-
bronchodilator decreases with age
decrease in post-bronchodilator greater in severe vs
nonsevere asthma with age
Airway lability11,25,26
Bronchial hyperresponsiveness decreases during school age greater in asthma, decrease during puberty could account
for remission in some young adults
Bronchodilator responsiveness decreases loss greater in severe asthma, a factor for progressive
airﬂow limitation
Mechanical properties14,17–21
Lung compliance decreases; hence, elastic recoil pressure increases airways close at a volume larger than FRC in preschool
children; little change in adults
Chest wall compliance decreases rib cage distortion and unstable FRC in preschool children
Speciﬁc airway resistance corrected for FRC increases trajectory of increase greater in children with asthma
Peripheral airway resistance decreases abruptly from preschool to school age higher in asthma
Ventilation heterogeneity22–24
Ventilation defects on inhaled
hyperpolarized noble gas MRI
nonventilated regions increase with age greater nonventilated regions in severe vs nonsevere
asthma
Total resistance (R5) − proximal resistance
(R20) by forced oscillometry
positive correlation with degree of peripheral ventilation
heterogeneity
greater in children with poorly controlled asthma
Lung clearance index by multiple-breath
nitrogen washout
increases with age prolonged clearance in children with asthma despite
normal FEV1
Abbreviations: COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 second; FRC, functional residual capacity; FVC, forced vital capacity; MRI,
magnetic resonance imaging; R20, large airway resistance at 20 Hz; R5, total respiratory resistance measured at 5 Hz.
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Switch to low-dose ICS/LABA
OR increase ICS dose
OR add LTRA
Stepping up from GINA STEP 2 to STEP 3 - PATIENT PROFILE:
Poorly or not well controlled asthma according to a carefully documented 
history and/or validated instrument (eg, ACT, ACQ, cATAQ) for ≥ 1 mo or ≥ 
2 exacerbations requiring OCS in past year, despite preferred treatment for 
mild, persistent asthma (ie, low dose ICS monotherapy) and optimal 
adherence*
3-month therapeutic trial with 
reassessment at 2-5 weeks
Stepping up from GINA STEP 1 to STEP 2 - PATIENT PROFILE:
Not well controlled asthma according to a validated instrument (eg, ACT, ACQ, 
cATAQ) for ≥ 2 month; asthma symptoms or needs prn SABA ≥ 2x/wk (but not 
daily) or who wakes due to asthma ≥ 1x/mo. Also consider for adolescent 
with infrequent asthma symptoms, but at risk for exacerbations (eg, ≥ 1 
exacerbation requiring OCS, ED visit, or hospitalization in past year)*
Daily low-dose ICS
OR prn ICS (given at same time as SABA)
OR LTRA 
1-3-month therapeutic trial with 
reassessment at 2-5 weeks
Continue to optimize medication:
• Increase to medium, then high dose ICS/LABA, AND/OR
• Add tiotropium soft mist inhaler, AND/OR
• Switch ICS to small particle ICS, OR
• Add LTRA to ICS, OR
• Budesonide/formoterol as controller and reliever (not approved in 
US for this indication) 
Stepping up from GINA STEP 3 to STEP 4 - PATIENT PROFILE:
Poorly or not well controlled asthma according to a carefully documented 
history and/or validated instrument (eg, ACT, ACQ, cATAQ) for ≥ 1 mo or 
who experienced a severe exacerbation requiring OCS, an ED visit, or 
hospitalization while  on Step 3 therapy (ie, low dose  ICS/LABA, medium 
dose ICS, or ICS+LTRA) and optimal adherence*
Referral to 
asthma specialist
Length of therapeutic trial determined 
individually  by desired outcome (usually 
reduction in exacerbations) and clinical urgency
Consider referral to 
asthma specialist
Adolescents
3-month therapeutic trial with 
interval reassessment
Stepping up from GINA STEP 4 to STEP 5 - PATIENT PROFILE:
Difficult-to-treat asthma: Poorly or not well controlled asthma according to a 
carefully documented history and/or validated instrument (eg, ACT, ACQ, 
cATAQ) for ≥ 2 mo or who experienced a severe exacerbation requiring OCS, 
an ED visit, or hospitalization while on Step 4 therapy (ie, medium or high 
dose  ICS/LABA, medium dose ICS + tiotropium and/or LTRA) and optimal 
adherence*
Biologic therapy should be considered as 
described in the text 
Asthma 
specialist care 
required
*Prior to stepping up therapy, confirm that the increased level of symptoms is due to asthma. 
The patient should be assessed for non-adherence with the management plan, potential 
comorbidities, and other factors that might negatively impact response to therapy (see Table 3), 
including an age-appropriate understanding of asthma and the management plan as well as 
parent and/or caregiver knowledge.  
Figure 1. The Pediatric Asthma Yardstick ﬂowchart. Patient proﬁles and recommendations for treatment for the 3 age groups of childhood are shown: adolescence (12–18
years old), school age (6–11 years old), and preschool (≤5 years old). Strategies are based on available guidelines, newer data, and the authors’ clinical experience as de-
scribed in the text. ACQ, Asthma Control Questionnaire; ACT, Asthma Control Test; cATAQ, Asthma Therapy Assessment Questionnaire for Children and Adolescents; ED,
emergency department; FP, ﬂuticasone propionate; GINA, Global Initiative for Asthma; ICS, inhaled corticosteroid; LTRA, leukotriene receptor antagonist; OCS, oral corti-
costeroid; PACT, Pediatric Asthma Control Test; SABA, short-acting β2-agonist.
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• To minimize the risk of asthma exacerbations, impaired lung
function, and medication side effects
When and how to implement a step-up in therapy is not
always clear. As shown in Figure 3, consideration for a sustained
step-up is recommended when disease control is suboptimal
during several months (eg, 1–3 months) of appropriate treatment.2
Validated tools for self-assessing control and treatment response—
such as the Asthma Control Test,31–33 the Childhood Asthma Control
Test,34,35 the Asthma Control Questionnaire (ACQ),36,37 the Child-
hood Asthma Control Questionnaire,38 the Asthma Therapy
Assessment Questionnaire for Children and Adolescents,39 the
Test for Respiratory and Asthma Control in Kids (TRACK),40,41 and
the Composite Asthma Severity Index42,43—can be helpful. These
are presented in eTable 2.
Although strategies provide speciﬁc recommendations for step-
ping up treatment,2,3 suggested protocols for 1 age group might not
be applicable to the others. For example:
Switch to low-dose ICS/LABA
OR increase ICS dose
OR add LTRA 
Stepping up from GINA STEP 2 to STEP 3 - PATIENT PROFILE:
Poorly or not well controlled asthma according to a carefully documented 
history and/or validated instrument (eg, cACT, ACQ, cATAQ) for ≥ 1 mo or 
≥ 2 exacerbations requiring OCS in past year, despite preferred treatment 
for mild, persistent asthma (ie, low dose ICS monotherapy) and optimal 
adherence*
3-month therapeutic trial with 
reassessment at 2-5 weeks
Daily low-dose ICS
OR prn ICS (given at same time as SABA)
OR LTRA 
Stepping up from GINA STEP 1 to STEP 2 - PATIENT PROFILE:
Not well controlled asthma according to a validated instrument (eg, PACT, 
ACQ, cATAQ) for ≥ 2 mo; asthma symptoms or needs prn SABA ≥ 2x/wk (but 
not daily) or who wakes due to asthma ≥ 1x/mo. Also consider for child with 
infrequent asthma symptoms, but at risk for exacerbations (eg, ≥ 1 
exacerbation requiring OCS, ED visit, or hospitalization in past year)*
1-3-month therapeutic trial with 
reassessment at 2-5 weeks
Continue to optimize medication:
• Increase to medium, then high dose ICS/LABA, AND/OR
• Add tiotropium soft mist inhaler, AND/OR
• Switch ICS to small particle ICS, OR
• Add LTRA to ICS, OR
• Budesonide/formoterol as controller and reliever (not approved in 
US for this indication)
Referral to pediatric 
asthma specialist
Length of therapeutic trial determined 
individually  by desired outcome (usually 
reduction in exacerbations) and clinical urgency
Stepping up from GINA STEP 3 to STEP 4 - PATIENT PROFILE:
Poorly or not well controlled asthma according to a carefully 
documented history and/or validated instrument (eg, cACT, ACQ, 
cATAQ) for ≥ 2 mo or who experienced a severe exacerbation requiring 
OCS, an ED visit, or hospitalization while on Step 3 therapy (ie, low dose  
ICS/LABA, medium dose ICS, or ICS+LTRA) and optimal adherence*
Consider referral to 
pediatric asthma 
specialist
School-age Children
3-month therapeutic trial with 
interval reassessment
Stepping up from GINA STEP 4 to STEP 5 - PATIENT PROFILE:
Difficult-to-treat asthma: Poorly or not well controlled asthma according to a 
carefully documented history and/or validated instrument (eg, cACT, ACQ, 
cATAQ) for ≥2 mo or who experienced a severe exacerbation requiring OCS, 
an ED visit, or hospitalization while on Step 4 therapy (ie, medium dose  
ICS/LABA, medium dose ICS + tiotropium and/or LTRA) and optimal adherence*
Biologic therapy should be considered as 
described in the text 
Pediatric 
asthma 
specialist care 
required
*Prior to stepping up therapy, confirm that the increased level of symptoms is due to 
asthma. The patient should be assessed for non-adherence with the management plan, 
potential comorbidities, and other factors that might negatively impact response to 
therapy (see Table 3), including an age-appropriate understanding of asthma and the 
management plan as well as parent and/or caregiver knowledge.
Figure 1. (continued)
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• The diagnosis and management of asthma differ among the age
groups, reﬂecting not only developmental issues but also chal-
lenges relating to daily activities (eg, information for caregivers,
teachers, camp counselors, coaches about asthma and its treat-
ment and permissions to administer treatment).2,3
• Although asthma often begins during early childhood, diagnos-
ing asthma in the very young child is challenging because it is
based largely on symptoms and is not easily supplemented by
lung function because of diﬃculty in obtaining quality test results.
The symptoms, notably wheezing and coughing, often are related
to, or occur in the context of, common viral infections.2,3 Rec-
ommendations guiding the diagnosis of asthma in young children
are presented in Table 2. The National Asthma Education and Pre-
vention Program (NAEPP) guidelines3 and the Global Initiative
for Asthma (GINA) management strategy provide more com-
prehensive recommendations.2
• The responsiveness of children to speciﬁc classes of medica-
tions can differ by age and from that observed in adults.29,44–47
Inconsistencies in response to medications can reﬂect differ-
ences in pulmonary physiology, inﬂammatory pathology, and/
or symptom presentation and persistence.29,44,45,48 They also can
reﬂect other factors such as comorbid conditions, suboptimal
inhaled drug delivery, and nonadherence with treatment. Table 3
lists some common factors contributing to failure to achieve, or
loss of, asthma control, aside from the pathophysiology itself.
Before adjusting therapy, it is important to ensure that the child’s
change in symptoms is due to asthma and not to any of these
factors that need to be addressed.
• The age of the child and the physiologic features of the devel-
oping respiratory system determine the optimal selection of
delivery devices to administer inhaled medication. Deposition
of inhaled particles including medications in the distal lung is
affected by inspiratory ﬂow velocity and particle size.49 Pre-
school children are at a particular disadvantage because they
might not be able to follow instructions to take a deep, slow
breath so that relatively more medication affects the orophar-
ynx. For this reason, jet nebulizers are commonly used in this
age group, with the relative advantages of being effective with
tidal breathing, not requiring a tight seal, and being used
conﬁdently in the face of respiratory distress.2 More
information on selection of delivery devices is provided in
eCommentary 1.
• Pediatric data are limited owing to a paucity of robust random-
ized controlled clinical trials in children. The eﬃcacy and safety
of medications can differ from those for adults, particularly in
younger children.29,46,48,50,51
Daily low-dose ICS
OR LTRA
OR intermittent high-dose ICS
Double low-dose ICS
OR add LTRA to low-dose ICS
Stepping up from GINA STEP 2 to STEP 3 - PATIENT PROFILE:
Wheezing with or without coughing ≥2x/wk or who wakes due to 
wheezing  ≥1x/mo, or has a  ≥10 point decrease in TRACK score after 3 mo
of treatment with low-dose ICS and/or has had ≥2 exacerbations requiring 
OCS, ED visit, or hospitalization in past year.*
3-month therapeutic trial with 
reassessment at 2-5 weeks
Stepping up from GINA STEP 1 to STEP 2 - PATIENT PROFILE:
Wheezing with or without coughing ≥2x/wk or who wakes due to wheezing 
≥1x/mo, or has a  ≥10 point decrease in TRACK score, and/or ≥2 exacerbations 
requiring OCS, ED visit, or hospitalization in past year despite using as-needed 
ICS or LTRA (given at same time as SABA) for intermittent asthma.*
3-month therapeutic trial with 
reassessment at 2-5 weeks
Continue to optimize medication:
• Increase to higher dose ICS with or without LTRA
• Consider ICS/LABA (FP/salmeterol is approved down to 
age 4 years)
Stepping up from GINA STEP 3 to STEP 4 - PATIENT PROFILE:
Wheezing with or without coughing throughout most days or who 
wakes due to wheezing >1x/wk and has a  ≥10 point decrease in TRACK 
score  after 3 mo of treatment with double low-dose ICS (with or 
without LTRA) and/or whose daily activity is limited by symptoms 
and/or has had ≥3 exacerbations requiring OCS, ED visit, or 
hospitalization in past year.*
3-month therapeutic trial with 
reassessment at 2-5 weeks
Referral to 
pediatric 
asthma 
specialist
Referral to 
pediatric 
asthma 
specialist
Referral to 
pediatric 
asthma 
specialist
Young Children
*Prior to stepping up therapy, confirm that the increased level of symptoms is due to 
asthma. The patient should be assessed for non-adherence with the management plan, 
potential comorbidities, and other factors that might negatively impact response to 
therapy, (see Table 3) including an age-appropriate understanding of asthma and the 
management plan as well as parent and/or caregiver knowledge.
**Given at same time as albuterol. 
Figure 1. (continued)
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The Pediatric Asthma Yardstick addresses these issues accord-
ing to the 3 age ranges comprising childhood—adolescents (12–
18 years old), school-age children (6–11 years old), and infants and
young children (≤5 years old)—with severity classiﬁcations as sub-
sections. The development of this document is described in
eCommentary 2.
Stepping Up Therapy
Step-Up Therapy for the Adolescent (12–18 Years Old) with Asthma
Step 1: intermittent asthma
The diagnosis of asthma in adolescents, like adults, is based on
a characteristic pattern of respiratory symptoms (eg, wheezing,
STEP 5
STEP 4
STEP 2
STEP 3
STEP 1 Low dose ICS
Low dose 
ICS/LABA for ages 
≥ 12 yr
Medium dose ICS 
for ages 6-11 yr
Medium or high 
dose ICS/LABA
Refer for add-on Tx
(e.g., anti-IgE)
Preferred
Controller
Other
Controller
Options
Consider 
low dose 
ICS
Medium-high 
dose ICS; or
low dose 
ICS+LTRA; or
low dose ICS+ 
theophylline
LTRA; or low 
dose 
theophylline
Add 
tiotropium;* or
high dose 
ICS+LTRA; or
high dose ICS+ 
theophylline
Add tiotropium;* 
add low dose OCS
Reliever
As needed short-acting 
β2-agonist
As needed short-acting β2-agonist 
or low dose ICS/LABA**
Adolescents and School-age Children
*Tiotropium by soft-mist inhaler is indicated as add-on treatment for patients with a history of exacerbations; it is not             
indicated in children <18 years
**For patients prescribed beclomethasone/formoterol or budesonide/formoterol
STEP 4
STEP 2
STEP 3
STEP 1 Daily low 
dose ICS
Double the daily low 
dose ICS
Continue daily controller 
and refer to specialist for  
assessment
Preferred
Controller
Other
Controller
Options
Low dose ICS+LTRALTRA; intermittent 
ICS
Add LTRA; increase 
ICS frequency; add 
intermittent ICS
Reliever As needed short-acting β2-agonist
Young Children
Sx consistent with 
asthma & poorly 
controlled or ≥ 3  
exacerbations/yr
Sx not consistent with 
asthma but frequent 
wheezing episodes –
dx trial of 3 mo
Infrequent 
viral 
wheezing 
and few or 
no interval 
sx
Asthma dx but not 
well controlled on ICS
Asthma dx but not 
well controlled on 
double  ICSConsider this
step for
children with:
Figure 2. Step therapy for children with asthma according to the Global Initiative for Asthma in 2017.2 ED, emergency department; ICS, inhaled corticosteroid; IgE, im-
munoglobulin E; LTRA, leukotriene receptor antagonist; OCS, oral corticosteroid; SABA, short-acting β2-agonist.
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shortness of breath [dyspnea], chest tightness, and/or cough) and
variable reversible expiratory airﬂow limitation. Differentiating
asthma symptoms from other acute or chronic respiratory condi-
tions (eg, hyperventilation, vocal cord dysfunction, deconditioning,
etc) is important. Documenting the diagnosis of asthma is well
covered by current guidelines.2,3
Treatment, too, is similar to that in adults, because many studies
have included adolescents (≥12 years old). For adolescents with in-
termittent asthma, the most common treatment is an as-needed
short-acting β2-agonist (SABA; Fig 2A), whereas low-dose ICS
(Table 4) or intermittent ICS can be considered an option, possibly
increasing the frequency of symptom-free days, decreasing exac-
erbations, and decreasing the potential decline in lung function over
time.2,52 A post hoc eﬃcacy analysis of the Steroid Treatment as
Regular Therapy (START) study that followed 7,138 patients (4–66
years old) with mild recent-onset (≤2 years) asthma treated for 3
years with low-dose budesonide (n = 3,577) or placebo (n = 3,561)
did not support restricting ICS to patients with symptoms occur-
ring more than 2 days a week53 (eTable 3).
Step-up options are summarized below for mild persistent and
moderate persistent asthma; the reader is directed to current guide-
lines and to the Adult Asthma Yardstick for a more comprehensive
discussion.1–3 Adolescents with severe and diﬃcult-to-treat asthma
present different challenges than adults with such asthma and those
sections are addressed in greater detail.
Step-up: intermittent asthma to mild persistent asthma (GINA step 1
to step 2)
Figure 3. When should a sustained step-up in asthma therapy be considered?1,2 FEV1, forced expiratory volume in 1 second; PEF, peak expiratory ﬂow.
Table 2
Differential Diagnosis of Asthma in the Young Child2
Condition Characteristics
Recurrent viral respiratory
tract infections
recurrent cough; runny and congested nose (usually <10 days); mild wheeze with infection; there might be no symptoms between infections
Gastroesophageal reﬂux cough when feeding; recurrent chest infections; vomits easily especially after a large feeding; poor response to trial of asthma medication
Foreign body aspirations acute episode of abrupt severe cough or stridor during feeding or play; recurrent chest infections and cough; focal lung signs
Tracheomalacia noisy breathing during crying, eating, and/or upper airway infections (noisy inspiration if extrathoracic, noisy expiration if intrathoracic);
harsh cough; inspiratory or expiratory retraction; symptoms often present since birth; poor response to trial of asthma medication
Tuberculosis persistent noisy respirations and cough; fever unresponsive to normal antibiotics; enlarged lymph nodes; contact with someone who has
tuberculosis; poor response to trial of asthma medication
Congenital heart disease cardiac murmur; cyanosis when eating; failure to thrive; tachycardia; tachypnea or hepatomegaly
Cystic ﬁbrosis cough starting shortly after birth; recurrent chest infections; failure to thrive (malabsorption); loose, greasy, bulky stools; poor response to
trial of asthma medication
Primary ciliary dyskinesia cough; recurrent mild chest infections; chronic ear infections and purulent nasal discharge; ~ 50% of children show situs inversus
Vascular ring respirations often persistently noisy; poor response to trial of asthma medication
Bronchopulmonary
dysplasia
premature birth; very low birthweight; needed prolonged mechanical ventilation or supplemental oxygen; diﬃculty breathing present since
birth
Immune deﬁciency recurrent fevers and infections (including nonrespiratory); failure to thrive
Patient Proﬁle
This proﬁle addresses the adolescent with asthma symptoms
or as-needed SABA use at least 2 times a week, but not daily,
or who wakes due to asthma at least once a month but less
than twice weekly. A step-up in treatment also can be consid-
ered for the adolescent who has infrequent asthma symptoms
but is at risk for exacerbations (eg, who has had ≥1 exacerba-
tion requiring an oral corticosteroid [OCS], ED visit, or
hospitalization in the past year). Infrequently, an adolescent
might present with no symptoms but abnormal lung function
and should be monitored, with any decision to treat based on
a risk-beneﬁt discussion among the physician, adolescent, and
family.
For all adolescents with asthma, before stepping up therapy, it
is important to conﬁrm that the increased level of symptoms is
due to asthma. The adolescent should be assessed for an age-
appropriate understanding of asthma and the management plan
in addition to parent and/or caregiver knowledge, nonadher-
ence with the management plan, potential comorbidities, and
other factors that might negatively affect response to therapy
(Table 3).
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• The preferred step-up from step 1 to step 2 for adolescents is
daily low-dose ICS2,3 (Fig 2A; see Table 4 for ICS dosing). Lower
pulmonary function and evidence of allergic inﬂammation (eg,
immunoglobulin E [IgE], fractional exhaled nitric oxide [FeNO],
blood eosinophils, eosinophil cationic protein) have been iden-
tiﬁed as predictors of favorable response to ICS over other
therapies.54–58
• Leukotriene receptor antagonists (LTRAs), although less effec-
tive than ICSs for most patients, are an option for adolescents
who cannot, or prefer to not, use an ICS.2,45,59,60 A high urinary
leukotriene E4 level (which might not be readily available) and/
or low (or no) levels of indicators of allergic inﬂammation might
help predict a favorable response.54
• Symptom reduction is the preferred outcome, and a 1- to
3-month therapeutic trial should be suﬃcient. Interval reas-
sessment is recommended.
• A challenge when addressing inadequate disease control in ado-
lescents is the need for the adolescent to recognize symptoms
and agree that better control is desired.61 Regular reassess-
ment is particularly important, working with the adolescent to
adjust therapy as needed to maintain disease control while at
the same time accommodating their changing needs and pref-
erences. Adolescence also is a period during which stress can
signiﬁcantly affect disease outcomes.62,63 Suggestions for en-
couraging adolescents to participate in their care can be found
in guidance documents and the published literature.3,64,65
Step-up: mild persistent asthma to moderate persistent asthma
(GINA step 2 to step 3)
• The preferred step-up for adolescents with persistent symp-
toms despite using recommended therapy for mild persistent
asthma is a low-dose combination of an ICS and a long-acting
β2-agonist (LABA).1,2 Studies in adults and adolescents and pe-
diatric trials including adolescents have shown the combination
to provide equivalent or better asthma control to ICS
monotherapy, as evidenced by less need for rescue medica-
tion, fewer nights with disturbed sleep, and more symptom-
free days, with no difference in the risk of serious adverse
events66–70 (eTable 3). Whether adding LABA can yield equiva-
lent asthma control at a lower ICS dose—a goal for treatment and
suggested by 1 26-week study in children (6–16 years
old)71—requires conﬁrmation.
• Alternative strategies include increasing the dose of ICS
monotherapy or adding a LTRA to an ICS.2,69 These strategies were
examined in the Best Add-On Giving Effective Response (BADGER)
study, a crossover comparison of these 3 commonly used step-
up protocols—adding LABA, increasing the dose of ICS
monotherapy 2.5-fold, and adding LTRA—for children with un-
controlled asthma despite guideline-based treatment for mild
persistent asthma (ie, low-dose ICS: 100 μg of ﬂuticasone pro-
pionate [FP] twice daily)69 (eTable 3). Although the best response
occurred most frequently with the LABA step-up, some chil-
dren responded better to increasing ICSmonotherapy or to adding
LTRA. Which therapy was best for which patient could not be
predicted by a priori baseline characteristics, but subsequent post
hoc analyses indicated some potential baseline factors that might
be predictive, including race and ethnicity, eczema, urinary
Table 3
Some Common Factors Leading to Failure to Achieve or Loss of Asthma Control2,49
Environmental exposures (eg, allergens, irritants, viruses)
Comorbid conditions contributing to morbidity (eg, rhinosinusitis, obesity;
respiratory infection, gastroesophageal reﬂux disease)
Diﬃculty using inhalers; improper technique
Poor adherence to the management plan, which could reﬂect
Fear of medication adverse effects
Poor understanding of treatment
Belief that the medication does not help (eg, in relation to patients reporting
that they cannot feel an immediate effect)
Belief that even controller medication can be taken intermittently (eg, when
symptoms become “noticeable”)
Inconvenience, including using multiple medications or inhalers and having to
take medications several times a day
Dislike of provider; distrust of medical establishments
Just “not wanting” to have to take medication (particularly for adolescents)
Not recognizing symptoms or ignoring the need for using medication; belief
that the medication is not necessary (particularly for adolescents)
Lack of parental support in following treatment plan
Family stress, emotional upsets; violence
Cost, including lack of insurance or medication not covered by insurance
Lack of access to health care
Table 4
Inhaled Corticosteroid Dosing for Children2
Drug Daily dose (μg)
Low dosea Medium dose High dose
Adolescents (≥12 y old and adults)
Beclomethasone dipropionate (HFA) 100–200 >200–400 >400
Budesonide (DPI) 200–400 >400–800 >800
Ciclesonide (HFA) 80–160 >160–320 >320
Fluticasone furoate (DPI) 100 N/A 200
Fluticasone propionate (DPI) 100–250 >250–500 >500
Fluticasone propionate (HFA) 100–250 >250–500 >500
Mometasone furoate 110–220 >220–440 >440
Triamcinolone acetonide 400–1,000 >1,000–2,000 >2,000
School-age children (6–11 y old)
Beclomethasone dipropionate (HFA) 50–100 >100–200 >200
Budesonide (DPI) 100–200 >200–400 >400
Budesonide (nebules) 250–500 >500–1000 >1000
Ciclesonide (HFA) 80 >80–160 >160
Fluticasone furoate (DPI) b b b
Fluticasone propionate (DPI) 100–200 >200–400 >400
Fluticasone propionate (HFA) 100–200 >200–500 >500
Mometasone furoate 110 220– < 440 ≥440
Triamcinolone acetonide 400–800 >800–1,200 >1,200
Young children (≤5 y old)
Beclomethasone dipropionate (HFA) 100
Budesonide (DPI) b
Budesonide pMDI + spacer 200
Budesonide (nebules) 500
Ciclesonide (HFA) 160
Fluticasone furoate (DPI) b
Fluticasone propionate (DPI) b
Fluticasone propionate (HFA) 100
Mometasone furoate b
Triamcinolone acetonide b
Abbreviations: DPI, dry powder inhaler; HFA, hydroﬂuoroalkane; N/A, not applica-
ble; pMDI, pressurized metered-dose inhaler.
aThis is not a table of equivalence. A low daily dose in young children is deﬁned as
the dose not associated with clinically adverse effects in trials that included mea-
sures of safety. Increasing the dose in this age group usually is a doubling of the
“low dose” as described in the text.
bNot studied in this age group.
Patient Proﬁle
This proﬁle concerns the adolescent with poorly or not
wellcontrolled asthma according to a carefully documented
history and/or a validated instrument (eTable 2) for at least 1
month or who had at least 2 exacerbations requiring OCS in the
past year, despite preferred treatment (low-dose ICS
monotherapy) for mild persistent asthma.
Before stepping up therapy, it is important to conﬁrm that the
increased level of symptoms is due to asthma, as described in
the proﬁle for the initial step-up, GINA step 1 to step 2.
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leukotriene E4, and, possibly, lung function.47,71 These are pre-
sented in eTable 3.
• Replacing a conventional ICS with a small-particle ICS formu-
lation might be another option,72 but safety concerns remain
regarding the potential for greater systemic absorption.73 More
data are needed.
• Low-dose budesonide plus formoterol as maintenance and re-
liever medication might decrease the risk of exacerbations
compared with budesonide alone,2,74 but this approach has not
received Food and Drug Administration (FDA) approval. Similar
data for other ICS and LABA combinations are limited, and an
as-needed SABA should be used as relievermedicationwith those
agents as directed by current guidelines.2,3
• The addition of dust mite sublingual immunotherapy could be
a step-up option for some adolescents with asthma and dust mite
allergy.75 In the United States sublingual dust mite immuno-
therapy is indicated for patients older than 18 years with allergic
rhinitis.76
• A 3-month trial with interval reassessment based on impair-
ment and risk should be suﬃcient to evaluate the success of
treatment.
Step-up: moderate persistent asthma to severe persistent asthma
(GINA step 3 to step 4)
The clinical burden is great in adolescents with severe and/or
diﬃcult-to-treat asthma, many of whom have symptoms despite
GINA step 3 or higher-level asthma therapy.2,77 This level of sever-
ity is often associated with very poorly controlled asthma symptoms
despite the use of multiple controller medications; frequent exac-
erbations requiring urgent care and even hospitalizations; impaired
lung function; impaired quality of life including negative effects on
sleep, daily activities, and emotions; and high direct and indirect
costs.7,30,78 Identifying and then improving the care and outcomes
of these severe and/or diﬃcult-to-treat adolescents (and chil-
dren) remain major clinical challenges. Most importantly, and
different from adults, physicians must address the potential risks
associated with more intensive treatment including (1) the poten-
tial adverse effects associated with higher ICS dosages (eg, growth
effects, suppression of the hypothalamic-pituitary-adrenal axis,
weight gain), (2) the stigma associated with being labeled as having
“severe” asthma, and (3) challenges with the need for greater sur-
veillance of control.2
The National Institute of Allergy and Infectious Disease Inner City
Asthma Consortium (ICAC) has identiﬁed characteristics differen-
tiating easy-to-control asthma (deﬁned as controlled with ≤100 μg/d
of FP) from diﬃcult-to-control asthma (deﬁned as requiring daily
therapywith ≥500 μg of FP ± LABA) in these patients based on a year-
long prospective study of 619 urban children (6–17 years old) who
had been receiving guideline-based care79 (eTable 3). At baseline
40.9% (n = 253) of the children were identiﬁed as having diﬃcult-
to-control disease, and 37.5% (n = 232) had easy-to-control disease;
the remainder did not match the criteria for either group. Over the
course of the year, controller use decreased signiﬁcantly in the easy-
to-control group; but despite optimal treatment and good adherence,
children with diﬃcult-to-control asthma showed little improve-
ment in symptoms, exacerbations, and pulmonary function.79 A sub-
analysis evaluated baseline variables that might distinguish diﬃcult-
to-control from easy-to-control subgroups. FEV1 and bronchodilator
responsiveness were key factors; others included Childhood Asthma
Control Test score, evidence of allergen sensitization, severity of rhi-
nitis, and body mass index percentile.79
Referral to an asthma specialist (allergist/pulmonologist) is
strongly recommended before stepping up fromGINA step 3 therapy.
Asthma specialists have the expertise and time to manage more
severe asthma, and better outcomes for these patients compared
with non-asthma specialists have been documented.2,80–83
Current strategies recommend medium-dose ICS plus LABA in
ﬁxed combination as the preferred step 4 step-up treatment for ado-
lescents, based on studies conducted with adults and
adolescents.1–3,67,68 Fewer adolescents treated with FP plus salmeterol
(42 of 613, 6.9%) experienced severe asthma exacerbations vs FP
monotherapy at equivalent ICS dosage (64 of 615, 10.4%; hazard ratio
[HR] 0.65, 95% conﬁdence interval [CI] 0.44–0.95, P = .03).67 Low,
medium, and high doses of ICS were used in this study, but deter-
mination of effect by dose was not possible because eﬃcacy was
reported according to the combined data for all strengths. Like-
wise, although no difference in the time to the ﬁrst asthma
exacerbation was reported for adolescents treated with budesonide
plus formoterol (52 of 632, 8.2%) compared with budesonide
monotherapy (51 of 636, 8.0%) at equivalent ICS dosage (HR 1.04,
95% CI 0.71–1.54, P = .83), the risk of an exacerbationwas 16.5% lower
with the combination based on analysis of all subjects (adults and
adolescents: HR 0.84, 95% CI 0.74–0.94, P = .002).68 The combina-
tion also was statistically superior to monotherapy for parameters
of asthma control (ie, ACQ6 score, symptom-free days, night-time
awakenings, use of rescue medication). However, for these pa-
tients with more severe disease, decreasing the number of
exacerbations could be at least an equally important determinant
of control.
Other Options
Adding the long-acting muscarinic agent, tiotropium bromide,
by soft mist inhaler is an alternative option for maintenance therapy
in adolescents with poorly controlled asthma and a prior recent
history of asthma exacerbations, and the data in adolescents are
consistent with ﬁndings in adults.1,2,84–87
Studies in adolescents (12–17 years old) with uncontrolled
asthma (ACQ score ≥1.5) have evaluated tiotropium administered
by soft mist inhaler once daily as add-on therapy to ICS with or
without LTRA.84,86 In these studies, doses of 5 and 2.5 μg signiﬁ-
cantly improved the primary outcome, evening peak FEV1 response
3 hours after dosing compared with baseline, and secondary spi-
rometric outcomes (eg, FEV1 area under the curve, peak expiratory
ﬂow), with safety and tolerability comparable to placebo. The 5-μg
dose is not FDA approved for the treatment of asthma. The studies
are presented in eTable 3.
Adding a LTRA to an ICS is another option, albeit with lower ef-
ﬁcacy comparedwith other step-up strategies. Formore information,
the reader is directed to current guidelines and the Adult Asthma
Yardstick.1–3
Using budesonide plus formoterol as maintenance and reliever
medication could be an option,2 although this approach has not re-
ceived FDA approval. For more information, the reader is directed
to current guidelines and the Adult Asthma Yardstick.1,2
The duration of the therapeutic trial is determined by the desired
outcomes, which for adolescents with severe asthma is a decrease
Patient Proﬁle
This proﬁle concerns the adolescent with poorly or not well-
controlled asthma according to a carefully documented history
and/or a validated instrument (eTable 2) for at least 2 months
or who experienced a severe asthma exacerbation in the past
year requiring OCS or an ED visit or hospitalization while on step
3 therapy (ie, low-dose ICS plus LABA; medium-dose ICS
monotherapy; low-dose ICS plus LTRA).
Before stepping up therapy it is important to conﬁrm that the
increased level of symptoms is due to asthma, as described in
the proﬁle for the initial step-up, GINA step 1 to step 2.
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in exacerbations in addition to control of impairment. Three to 6
months might be needed to appropriately evaluate success.
Step-up: severe persistent asthma to severe diﬃcult-to-treat asthma
(GINA step 4 to step 5)
A subgroup of patients with severe asthma continue to experi-
ence exacerbations, poor symptom control, and/or diminished lung
function despite optimal adherence with anti-inﬂammatory and
bronchodilator medications, proper inhaler technique, and treat-
ment of coexisting conditions, and can be categorized as having
severe diﬃcult-to-control (or diﬃcult-to-treat) asthma.1,88–90 Data
are limited for adolescents (and children). In the Epidemiology and
Natural History of Asthma: Outcomes and Treatment Regimens
(TENOR) study, which included school-age children (6–12 years old,
n = 770), adolescents (13–17 years old, n = 497), and adults (≥18 years
old, n = 3,489), more than 55% of all patients, regardless of age, were
symptomatic despite using at least 3 asthma maintenance medi-
cations (eg, ICS, LABA, and LTRA)77,91 (eTable 3). Approximately 40%
of adolescents (and 50% of children) reported OCS courses and un-
scheduled visits despite their regular medications. In the ICAC study
identifying characteristics of diﬃcult-to-control asthma in school-
age children and adolescents (described in the previous section),
approximately 25% of the diﬃcult-to-control subgroup still had
asthma that was not controlled at the end of the study year despite
good adherence with treatment.79
Adolescents who remain symptomatic after a therapeutic trial
of step 4 care should be referred to an asthma specialist (if they
have not previously been) for evaluation and appropriate treatment.
Continued trials with increasing doses of medication—such as
high-dose ICS plus LABA—have been the usual therapeutic para-
digm for these adolescents, in similar manner to adults.1,2 Alternate
approaches to high-dose ICS plus LABA include adding tiotropium
or switching to (or adding) a small-particle ICS and/or increasing
the dose of ICS monotherapy with or without added LTRA, al-
though the latter might not be as successful as high-dose
combination treatment,92 and for some adolescents, switching to
a different delivery device might be helpful after assessing tech-
nique (Table 3).
For adolescents with severe diﬃcult-to-control asthma, a ther-
apeutic trial of at least 6 months with interval assessment for
impairment might be needed. Monitoring potential adverse effects
is important when higher doses of ICS are used.
Targeted Therapy: Biologics
When asthma remains uncontrolled despite a strategy of mul-
tiple medications or if the adolescent is sensitive to increasing the
ICS dose, the next step might be to attempt to target treatment ac-
cording to the underlying pathologic mechanisms.1,88,89 Identifying
the asthma phenotype and then implementing treatment that targets
the cellular inﬂammation in the airway has been shown to provide
clinical beneﬁt for some adults and adolescents with severe diﬃcult-
to-control asthma.1,88,89 This is an area of ongoing research with a
number of agents currently being reviewed at the FDA, including
for pediatric use.90–93
Referral to an appropriate asthma specialist who can evaluate
the adolescent for targeted therapy is important.
Targeting IgE: omalizumab
Omalizumab is a humanized monoclonal anti-IgE antibody that
inhibits binding of IgE to mast cells and decreases serum levels of
free IgE.94,95 It is FDA approved for children at least 6 years of age
with moderate-to-severe asthma. The dose and dosing frequency
are determined according to the total serum IgE level (internation-
al units per milliliter) determined before starting treatment and
bodyweight (kilograms).94
A therapeutic trial with omalizumab is recommended for pa-
tients withmoderate-to-severe allergic asthma for whom other add-
on therapies provide inconsistent or incomplete control, particularly
those with recurrent severe exacerbations.1,2,89 It also can be helpful
for patients with a history of poor asthma control and poor adher-
ence to ICS and conventional therapies.96 In studies in adolescents
(and children), omalizumab has lowered the frequency of asthma
exacerbations, ED visits, hospitalizations, and decreased the need
for rescue medications.97–103 Omalizumab has been studied as part
of the ICAC initiative103: the Inner-City Anti-IgE Therapy for Asthma
(ICATA) study98 and the subsequent Preventative Omalizumab or
Step-up Therapy for Fall Exacerbations (PROSE) study,104 which are
presented in eTable 3.
The PROSE study was conducted to evaluate the association
between omalizumab treatment and decrease in seasonal peaks
of asthma exacerbations observed in the ICATA data.98,104 This
potential preventive effect of omalizumab was assessed in com-
parison with regular guideline-based care or increased ICS
monotherapy. The study treatments were initiated 4 to 6 weeks
before the start of school and continued for 90 days. The fall
seasonal exacerbation rate was signiﬁcantly lower with omalizumab
vs placebo, particularly in children with more severe asthma—
those who required 500 mg of ﬂuticasone equivalent twice daily
(National Heart, Lung, and Blood Institute step 5 therapy or GINA
step 4) during run-in and/or those who had at least 1 exacerba-
tion during the same period.104 Increased peripheral blood eosinophil
counts and FeNO levels were associated with exacerbations
during run-in, suggesting that these children had higher
levels of inﬂammation despite appropriate guideline-directed
treatment.104,105
As with all biologics, omalizumab is expensive, and research into
speciﬁc biomarkers (eg, blood eosinophils, FeNO) and risk factors
(eg, rhinovirus infections) is ongoing to better identify patients who
Patient Proﬁle
This proﬁle concerns the adolescent with poorly or not well-
controlled persistent asthma according to a carefully documented
history and/or a validated instrument (eTable 2) for at least 2
months or who experienced at least 1 severe asthma exacerba-
tion requiring an OCS or an ED visit or hospitalization while on
step 4 therapy in the past year (ie, medium-dose ICS plus LABA;
medium-dose ICS plus tiotropium or plus LTRA).
Before stepping up therapy it is important to conﬁrm that the
increased level of symptoms is due to asthma, as described in
the proﬁle for the initial step-up, GINA step 1 to step 2.
Patient Proﬁle
This proﬁle concerns the adolescent with moderate-to-severe
allergic asthmawho has a total serum IgE level of 30 to 700 IU/mL
and demonstrates IgE-mediated hypersensitivity by curaneous
or in vitro testing to a perennial allergen (eg, house dust mite,
animal dander, cockroach, mold) and who is still symptomatic
(eg, poorly or not well-controlled asthma according to a vali-
dated instrument; eTable 2) or experiencing exacerbations while
taking high doses of anti-inﬂammatory and reliever medica-
tions or who might be sensitive to the adverse effects of higher
doses of ICS.
Before stepping up therapy it is important to conﬁrm that the
increased level of symptoms is due to asthma, as described in
the proﬁle for the initial step-up, GINA step 1 to step 2.
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will obtain the greatest beneﬁt from treatment. More information
is provided in eCommentary 3.
Long-term studies of up to 3 years in adults,106,107
adolescents,98,104,107 and children98,99,108 have shown omalizumab to
be well tolerated, and the improvement in symptoms and lung func-
tion to be maintained.
Targeting eosinophils: anti–interleukin-5
Treating the eosinophilic asthma phenotype has targeted mol-
ecules involved in the activation and recruitment of eosinophils, such
as the cytokine interleukin-5 (IL-5). This is described in greater detail
in the Adult Asthma Yardstick, including use of the 2 FDA-approved
IL-5 antagonist monoclonal antibodies to treat patients with severe
asthma, mepolizumab and reslizumab.1,109,110 Since publication of
the Adult Asthma Yardstick, the anti–IL-5 receptor α monoclonal
antibody, benralizumab, has been approved by the FDA as add-on
maintenance therapy for patients with severe eosinophilic asthma.111
Benralizumab and mepolizumab are approved for adolescent pa-
tients as young as 12 years.109,111
Mepolizumab is a humanized monoclonal antibody against IL-
5, which has been shown to decrease sputum and blood eosinophil
counts, usually within 1 month; clinical improvement can take
longer.112–114 It is administered by subcutaneous injection at a stan-
dard dose of 100 mg every 4 weeks.109 Current prescribing
parameters require a blood eosinophil threshold of at least 150 cells/
μL at treatment initiation or at least 300 cells/μL in the 12 months
before treatment initiation. Patients also must have uncontrolled
asthma despite receiving maximal standard therapy with a high-
dose ICS and at least 1 additional controller medication.109 Treatment
effectiveness is strongly associated with the exacerbation history
of the patient and peripheral eosinophil counts. Patients most likely
to experience a decrease in exacerbations are those with eosino-
phil counts of at least 300 cells/μL and at least 2 exacerbations in
the past year. Patients who have experienced more exacerbations
might respond despite eosinophil levels as low as 150 cells/
μL.109,112–114 For most patients, fewer exacerbations and health care
use are indicators of successful treatment. Additional data are war-
ranted because of the limited number of adolescents in the studies;
long-term use of mepolizumab in adolescents also is the subject
of ongoing clinical trials.
Benralizumab is a humanized, afucosylated anti–IL-5 receptor
α monoclonal antibody that binds to the IL-5 receptor α on eo-
sinophils, thereby inhibiting their proliferation and activation.110
Afucosylation of the oligosaccharide core of the antibody en-
hances binding to the FcγRIII α receptor on natural killer cells,
macrophages, and neutrophils, which increases antibody-dependent
cell-mediated cytotoxicity.115,116 Indicated for patients with a blood
eosinophil level of at least 300 cells/μL, it is administered by sub-
cutaneous injection as a standard 30-mg dose given every 4 weeks
for 3 doses and every 8 weeks thereafter.110 Studies have shown im-
provements in pulmonary function and quality of life and decreases
in exacerbations.117,118 However, only a limited number of adoles-
cent subjects were included; additional data are anticipated for this
age group.
Oral Corticosteroids
The over-prescription of OCSs for asthma is a concern, partic-
ularly for adolescents.119 A short-term course of daily or alternate-
day OCSs can be helpful for some adolescents with diﬃcult-to-
treat severe asthma, to help gain control while initiating other
therapies, including biological therapies, more so than for adults
with diﬃcult-to-control asthma.16 If OCSs are used, the adoles-
cent should be monitored for adverse events (eg, adrenal function,
growth, bone density) regularly and switched to other therapies
as soon as control is achieved.2 If an adolescent is receiving OCS
as maintenance therapy, the dose should be titrated to the lowest
dose that maintains adequate control to prevent asthma
exacerbations.
Step-Up Therapy for the School-Age Child (6–11 Years Old) with
Asthma
Step 1: intermittent asthma
Intermittent asthma in school-age children is diagnosed and
treated similarly to that in adolescents, as described in that section.
Diagnosis is based on the pattern of respiratory symptoms and eval-
uation of expiratory airﬂow limitation. Ensuring that the symptoms
are due to asthma is important (Table 3). Classiﬁcation of asthma
control for this age group is presented in Table 1B. Validated tools
can be helpful; eTable 2 presents those speciﬁc for children 4 to 11
years old.34,35
The usual treatment for intermittent asthma in school-age chil-
dren is an as-needed SABA with or without low-dose daily or
intermittent ICS2 (Fig 2A; see Table 4 for ICS dosing).
Step-up: intermittent asthma to mild persistent asthma (GINA step 1
to step 2)
For the 6- to 11-year-old child with persistent but mild symp-
toms, the preferred controller medication is daily low-dose ICS2,3
(Fig 2A; Table 4). If the child is already using a low-dose daily ICS
or intermittent ICS, increasing the dose or stepping up from inter-
mittent to daily dosing can be considered.2 Regular use of ICS has
been shown to decrease asthma symptoms, improve quality of life,
and decrease the risk of exacerbations for most school-age
Patient Proﬁle
This proﬁle concerns adolescents who are still symptomatic with
poorly or not well-controlled severe asthma according to a care-
fully documented history and/or a validated instrument (eTable 2)
despite treatment with high-dose ICS plus LABA and/or other
anti-inﬂammatory and reliever medications and who have ev-
idence of peripheral blood eosinophilia and frequent
exacerbations requiring OCSs.
Before stepping up therapy it is important to conﬁrm that the
increased level of symptoms is due to asthma, as described in
the proﬁle for the initial step-up, GINA step 1 to step 2.
Patient Proﬁle
This proﬁle concerns the child (6–11 years old) with asthma
symptoms or as-needed SABA use more than 2 times a week,
but not daily, or who wakes due to asthma more than twice
monthly but less than twice weekly. A step-up in treatment can
be considered for the child who has infrequent asthma symp-
toms but is at risk for exacerbations (eg, has had an exacerbation
requiring an OCS, ED visit, or hospitalization in the past year).
Infrequently, a child can present with no symptoms but abnor-
mal lung function and should be monitored, with any decision
to treat based on a risk-beneﬁt discussion among the physi-
cian, child, and family.
Before stepping up therapy, it is important to conﬁrm that the
increased level of symptoms is due to asthma. The child should
be assessed for an age-appropriate understanding of asthma and
the management plan in addition to parent and/or caregiver
knowledge, nonadherence with the management plan, poten-
tial comorbidities, and other factors that might negatively affect
the response to therapy (Table 3).
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children with mild persistent asthma.2 Predictors of a favorable re-
sponse to ICS include evidence of allergic inﬂammation (eg, IgE,
FeNO, eosinophil cationic protein, personal or family history) and,
in some cases, lower pulmonary function.54–56
Parents who might be averse to their child using an ICS should
be encouraged to ask questions and be educated to the clinical ben-
eﬁts and risk-beneﬁt ratio of using low-dose ICSs. Steroid phobia
needs to be addressed early.
Other Options
The LTRAs are often less effective than an ICS2,59,120 but can be
chosen as initial controller therapy for children who cannot use or
prefer to not use an ICS. LTRAs can be helpful for children with con-
comitant allergic rhinitis, particularly those with high urinary
leukotriene E4 levels, although measurement might not be readily
available.2,54
A therapeutic trial of 1 to 3 months with interval reassessment
of symptoms, daily activities, exacerbations, and lung function is
recommended.
Step-up: mild persistent asthma to moderate persistent asthma
(GINA step 2 to step 3)
It is suggested that children 6 to 11 years old be referred to an
asthma specialist for assessment and to review other potential prob-
lems affecting management before stepping up therapy from step
2 to step 3.2
The preferred step-up option for GINA step 2 to step 3 in chil-
dren 6 to 11 years old is a moderate-dose ICS2 (Fig 2A; Table 4).
However, based on the authors’ clinical experience and the eﬃca-
cy and safety studies described below, low-dose ICS plus LABA can
be considered.
Using low-dose ICS plus LABA in this age group is supported by
the BADGER study described earlier, which compared adding LABA,
LTRA, or more ICS to the therapy of children still symptomatic on
low-dose ICS69 (eTable 3). Overall, more children had a best re-
sponse to the LABA step-up than to adding a LTRA (52% vs 34%,
P = .02) or increasing the dose of ICS (52% vs 32%, P = .004). Age did
not predict response to treatment,69 although, as described earlier,
post hoc analyses (described in eTable 3) suggested that baseline
FEV1, race and ethnicity, and history of eczema might help predict
which therapy to use.46,69 Additional data are needed to conﬁrm the
ﬁndings.
A more recent prospective evaluation compared 26 weeks of
twice-daily treatment with FP plus salmeterol (100 plus 50 μg twice
daily or 250 plus 50 μg) or FP alone (100 or 250 μg) in children 4
to 11 years old who were using daily asthma medications and had
a history of exacerbations in the previous year.66 No between-
treatment differences were determined for the primary end point,
serious asthma-related adverse events, or secondary end points of
asthma control. The ﬁndings are similar to the previous study com-
paring FP plus salmeterol (100 plus 50 μg twice daily) with FP
monotherapy (200 μg twice daily) in children 6 to 16 years of age71
(eTable 3). In that study, the outcomes were similar between treat-
ments, but eﬃcacy was achieved with a lower dose of FP in the
combination arm. No between-treatment differences in growthwere
observed for the 26-week studies comparing FP plus salmeterol with
doubling the FP dose.66,71
The results of the BADGER study, which used FP and salmeterol
as the ICS and LABA, were similar to a year-long study in school-
age children (N = 341, 4–11 years old) that compared budesonide
monotherapy (320 μg) with the ﬁxed-dose combination of
budesonide and formoterol (80 and 4.5 μg) asmaintenance therapy121
(eTable 3). A third treatment group received the ﬁxed-dose ICS
plus LABA as maintenance therapy and as reliever therapy, an
approach not approved by the FDA. Using the budesonide plus
formoterol combination as maintenance and reliever therapy sig-
niﬁcantly decreased exacerbations and increased the time to ﬁrst
exacerbation compared with the other treatments. The adjusted
mean growth rate was signiﬁcantly greater (by approximately
1 cm) for children in the ICS plus LABA group compared with the
higher-dose budesonide group.121 In contrast, in children (5–11
years old) with mild-to-moderate persistent asthma using ICS
daily, quintupling the dose of ICS at the earliest signs of loss
of asthma control did not lower the severe exacerbation rate or
improve symptoms and could be associated with decreased linear
growth.122
The differences in results from these trials warrant longer-
term study. However, the outcomes underscore the need for regular
and careful monitoring and appropriately adjusting therapy to the
child (eTable 3).
Other Options
The utility of adding a LTRA to the ICS treatment of some
children as a step-up was demonstrated in the BADGER trial.69
Although the switch to ICS plus LABA produced the greatest
clinical beneﬁt for the largest proportion of children in the study,
some children did best with LTRA added to low-dose ICS, as
described in the previous section for adolescents and included in
eTable 3.47,70
Matched retrospective cohort analyses of school-age children (5–
11 years old) from large primary care databases have shown that
switching to a small-particle ICS (eg, beclomethasone, mass median
aerodynamic diameter 1.1 μm) has potential for clinical beneﬁt based
on risk domain measures and exacerbation rates.50 Compared with
doubling the ICS dose of a standard-particle formulation (eg,
ﬂuticasone, mass median aerodynamic diameter 2.4–3.2 μm), the
odds of the step-up improving asthma control measures were sig-
niﬁcantly greater for children using the small-particle ICS and
comparable to those using a ﬁxed-dose ICS plus LABA combina-
tion. This approach has not produced comparable results in
adolescents and adults,72 and safety concerns related to the poten-
tial for greater systemic absorption with the smaller particle73 need
to be addressed.
Another option for a step-up in school-age children is to add
tiotropium to a low-dose ICS. This strategy was tested in a dose-
ranging study of once-daily tiotropium (1.25, 2.5, 5 μg) by soft mist
inhaler added to the therapy of children (6–11 years old) who were
symptomatic despite treatment with low-dose ICS.123 All doses sig-
niﬁcantly improved measures of lung function compared with
placebo, and adverse events were similar between treatment groups.
Only the 2.5-μg dose is currently FDA approved for asthma in this
age group.
A therapeutic trial of up to 3 months with interval reassess-
ment of symptoms, daily activities, exacerbations, and impairment
is recommended.
Patient Proﬁle
This proﬁle concerns the 6- to 11-year-old child with poorly or
not well-controlled asthma according to a carefully docu-
mented history and/or a validated instrument (eTable 2) for at
least 1 month or who experienced at least 2 exacerbations re-
quiring OCS in the past year, despite preferred treatment (low-
dose ICS monotherapy) for mild persistent asthma.
Before stepping up therapy it is important to conﬁrm that the
increased level of symptoms is due to asthma, as described in
the proﬁle for the initial step-up, GINA step 1 to step 2
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Step-up: moderate persistent asthma to severe asthma (GINA step 3
to step 4)
It is recommended that children 6 to 11 years old be referred
to an asthma specialist for expert assessment and advice before step-
ping up therapy from step 3 to step 4.2
Medium- to high-dose ICS plus LABA ﬁxed combination, with
the ICS dose adjusted to age, is the preferred step-up therapy
according to GINA2 (Fig 2A, Table 4). The recommendation is
based on the limited data available for using LABA as add-on
treatment to ICS in children 6 to 11 years old and the clinical
beneﬁt of combination treatment observed in adolescents (and
adults) and described in previous sections. This recommendation
differs from NAEPP Expert Panel Report 3 guidelines, which date
back to 2007 and predate most of the clinical trial results cited
earlier, which recommend increasing the ICS dose as the pre-
ferred option.2,3
The safety of ICS plus LABA was evaluated in children 4 to 11
years of age using a ﬁxed combination of ﬂuticasone plus salmeterol
compared with ﬂuticasone monotherapy66 (eTable 3). No differ-
ences were determined for the time to the ﬁrst severe asthma
exacerbation (HR 0.85, 95% CI 0.73–1.01); overall, 265 of 3,107
children (8.5%) in the combination group had a severe exacerba-
tion compared with 309 of 3,101 children (10.0%) treated with
ﬂuticasone monotherapy. Similar ﬁndings were determined when
the data were analyzed separately for the 4- to 6- and 7- to
11-year-old groups.66 An eﬃcacy subgroup analysis based on treat-
ment and asthma control status at the start of the study showed a
lower HR for time to ﬁrst asthma exacerbation for the ICS plus
LABA combination compared with ﬂuticasone monotherapy (HR
0.75, 95% CI 0.57–0.98).66
Recently, a FDA review of 4 large clinical safety trials reported
that treating asthma with an ICS plus LABA combination did not
result in signiﬁcantly more serious asthma-related side effects than
ICS alone; and on December 20, 2017 the FDA removed the boxed
warning about asthma-related death from the drug labels of medi-
cines containing an ICS and a LABA.124 Based on the eﬃcacy and
safety data presented, the authors conclude that, given the reas-
suring data of ICS plus LABA safety in adults, adolescents67,68 and
children,66 current treatment protocols should be reassessed in future
guideline updates. For now, attention to individualizing treat-
ment in patients 6 to 11 years old using the ﬁndings of GINA step
4 data in adolescents and adults and GINA step 3 data in children
is recommended.
Other Options
Children 6 to 11 years of age with uncontrolled asthma (ACQ
score ≥1.5) were included in the dose-ranging study of tiotropium
(1.25, 2.5, 5 μg) as add-on therapy to ICS with or without LTRA, de-
scribed in the previous section (step 2 to step 3).123 The adjusted
mean peak FEV1 responses with all doses of tiotropium (1.25 μg:
261 mL; 2.5 μg: 290 mL; 5 μg: 272 mL) were signiﬁcantly greater
than with placebo (185 mL; P ≤ .001 for all comparisons) with no
differences in adverse effects. A recent study conducted in 400 chil-
dren 6 to 11 years old with severe symptomatic asthma showed
clinical beneﬁt with the addition of once-daily tiotropium added
to ICS and at least 1 controllermedication.125 Comparedwith placebo,
signiﬁcant improvements were observed in peak and trough FEV1
(P < .001, P = .01, respectively) with the 5-μg dose at 3-hours after
dosing, with no between-treatment differences for safety out-
comes, although at this time the 5-μg dose is not FDA approved for
this age group. These studies are presented in eTable 3.
High-dose ICS plus LTRA is an alternative treatment in school-
age children.2 Using budesonide plus formoterol combination as
maintenance and reliever medication at moderate to high ICS dose
also can be an option, but this approach has not received FDA ap-
proval in the United States.
The desired outcome for school-age children with severe asthma
is a decrease in exacerbations and resumption of normal activi-
ties. At least 6 months might be needed for a therapeutic trial when
exacerbations are the major reason for lack of control.
Step-up: severe persistent asthma to severe diﬃcult-to-treat asthma
(GINA step 4 to step 5)
Children requiring steps 4 and 5 care should be co-managed by
a pediatric asthma specialist.80–82 The initial strategy for stepping
up therapy is the same as for adolescents, described earlier—
namely adding and/or increasing the doses of medications. This
includes:
• A therapeutic trial of higher doses of ICS plus LABA (preferred
approach)2,92
• Increasing the dose of ICS monotherapy
• Higher doses of the combination of ICS and LTRA
• Adding tiotropium
• Using a small-particle ICS
• Addition of a biologic therapy based on patient characteristics
These approaches have been discussed in the adolescent section.
For these children with severe diﬃcult-to-control asthma, a ther-
apeutic trial of at least 3 to 6 months with interval assessment for
impairment might be needed.
Targeted Therapy: Biologics
Targeted therapies for severe diﬃcult-to-control asthma have
largely been studied in adults and, to some extent, in adolescents
as previously described. The monoclonal IgE antibody omalizumab
received FDA approval for use in school-age children (6–11 years
old) with allergic asthma in July 2016. Referral to an appropriate
asthma specialist is important. Other targeted therapies have not
yet been approved for use in this age group but are currently under
study.
Patient Proﬁle
This proﬁle concerns the 6- to 11-year-old child with poorly or
not well-controlled asthma according to a carefully docu-
mented history and/or a validated instrument (eTable 2) for at
least 2 months or who experienced a severe asthma exacerba-
tion requiring OCS or an ED visit or hospitalization in the past
year while on step 3 therapy (ie, low-dose ICS plus LABA;
medium-dose ICS monotherapy; low-dose ICS plus LTRA).
Before stepping up therapy it is important to conﬁrm that the
increased level of symptoms is due to asthma, as described in
the proﬁle for the initial step-up, GINA step 1 to step 2.
Patient Proﬁle
This proﬁle concerns the 6- to 11-year-old child with poorly or
not well-controlled asthma according to a carefully docu-
mented history and/or a validated instrument (eTable 2) for at
least 2 months or who experienced a severe asthma exacerba-
tion requiring OCS or an ED visit or hospitalization in the past
year while on step 4 therapy (ie, medium-dose ICS plus LABA;
medium-dose ICS plus tiotropium with or without LTRA).
Before stepping up therapy it is important to conﬁrm that the
increased level of symptoms is due to asthma, as described in
the proﬁle for the initial step-up, GINA step 1 to step 2.
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Targeting IgE: Omalizumab
Initial studies of omalizumab in school-age children showed a
corticosteroid-sparing effect concomitant with a decrease in asthma
exacerbations. These studies were conducted in children with
moderate-to-severe allergic asthma that was well controlled on ICS
(168–429 μg/d of beclomethasone dipropionate).126,127 Approximate-
ly 55% of omalizumab-treated children could completely withdraw
from their ICS during a 12-week steroid-reduction phase com-
pared with 39% of placebo-treated patients (P = .004). The decrease
in ICS use was maintained during a 24-week open-label extension
phase inwhich the placebo-treated patients were given omalizumab;
during this phase, 81.4% of all patients used no concomitant asthma
medication, and 90.8% of patients who had used omalizumab in the
initial study and had stopped ICS remained ICS free.126,127 Follow-
up analyses showed improvement in asthma-related quality of life128
and decreases in IgE and FeNO levels105,126,127 (eTable 3).
Similar results were subsequently reported for double-blinded,
placebo-controlled, prospective studies of school-age children with
allergic asthma uncontrolled on medium-high dose ICS with or
without other controller medications.102,129 Compared with placebo,
exacerbations decreased by more than 30% at week 24, with con-
tinued improvement throughout the year of treatment.
Sixty percent of children in the ICATA study (described in the
adolescent section and eTable 3) were 6 to 12 years old. In these
children, as in the adolescents, omalizumab improved asthma control
compared with placebo, evident as fewer symptom days and less
exacerbations and concomitant with an overall decrease in use of
controller medications, including ICS.98,103 In the PROSE study, de-
scribed earlier (eTable 3), omalizumab started shortly before the
fall return to school produced a decrease in fall seasonal exacer-
bations, particularly in children receiving higher step controller
therapy.104
Omalizumab has had pediatric approval in the European Union
for more than 7 years, and clinical experience from those coun-
tries supports the study data.99 Adding omalizumab to the treatment
of children with severe persistent allergic asthma can diminish the
burden of disease by improving asthma control, enhancing quality
of life, and decreasing corticosteroid use.97,108,130 Safety data from
studies and real-world experience show omalizumab treatment to
be well tolerated in school-age children with allergic asthma.99,131
Step-Up Therapy for the Young Child (≤5 Years Old) with Asthma
Up to 50% of children experience at least 1 acute episode of
wheezing before 6 years of age.45,132–135 Of these, approximately 30%
to 40% have recurrent wheezing132,134; and it is estimated that up
to 15% will develop asthma, continuing to wheeze beyond 6 years
of age.136,137 Therefore, evaluating wheezing in the young child (Fig 4;
Table 2) is very important. Regardless of asthma predictive status,
wheezing episodes in young children are associated with in-
creased morbidity and use of health care compared with school-
age children.16 Factors for identifying those children who are most
likely to develop asthma remain the subject of current study.
100%
Symptoms* during 
upper respiratory 
tract infections
Episodes/year
Symptoms* 
between episodes
*Cough, wheeze, heavy breathing 
% fitting these symptom patterns (below)
% likely to have asthma diagnosis or respond to   
regular controller treatment, based on symptom 
patterns (below)
> 10 days
> 3, or severe episodes 
and/or nighttime worsening
Occasional symptoms*
> 10 days
> 3, or severe episodes 
and/or nighttime worsening
Symptoms* during play or 
when laughing
Atopy or family history of 
asthma
< 10 days
2-3
None
SYMPTOM PATTERN (may change over time) 
% of children 
with viral-
induced wheeze
0
Figure 4. Patterns of symptoms when diagnosing asthma in the young child.2
Patient Proﬁle
This proﬁle concerns children 6 to 11 years old with moderate-
to-severe allergic asthma who have a total serum IgE level of 30
to 1,300 IU/mL and demonstrated IgE-mediated hypersensitiv-
ity by cutaneous or in vitro testing to a perennial allergen (eg,
house dust mite, animal dander, cockroach, mold) and who are
still symptomatic (eg, poorly or not well-controlled asthma ac-
cording to a validated instrument; eTable 2) or experiencing
exacerbations while taking high doses of anti-inﬂammatory and
reliever medications or who might be sensitive to the adverse
effects of higher doses of ICS.
Before stepping up therapy it is important to conﬁrm that the
increased level of symptoms is due to asthma, as described in
the proﬁle for the initial step-up GINA, step 1 to step 2.
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Step 1: intermittent asthma
Diagnosing asthma in the young child can be challenging,
requiring careful observation and monitoring on the part of the
clinician and the family. Because routine assessment of airﬂow
limitation is not generally available in this age group, the diagno-
sis of asthma is largely based on a probability analysis of symptom
patterns (Fig 4) and review of family medical history and physical
ﬁndings2 (Table 2). The key symptom for diagnosing asthma in
this age group is recurrent wheezing (with or without cough),
and occurrence during and between respiratory infections and in
relation to other triggers should be reviewed. Recurrent wheezing
is common in young children, often in relation to upper respirato-
ry tract infections, which in this age group can be frequent—at
least 6 to 8 times per year—and with some viral infections
occurring throughout childhood (eg, rhinovirus, respiratory syn-
cytial virus); other conditions also produce wheeze and can
masquerade as asthma in this age group2 (Table 2). A careful
differential assessment of cause for these episodic symptoms is
important. A positive family history of allergic disease or the
presence of atopic dermatitis or allergic sensitization can be
predictive, because early allergic sensitization to multiple aller-
gens increases the likelihood that a wheezing child will develop
persistent asthma.2,3,133,138,139 The Asthma Predictive Index (API)
and modiﬁed API (mAPI) are validated measures that have shown
good correlation with likelihood of developing asthma in the
young child; positive scores have been associated with risk of
persistent wheeze140–142 (see eCommentary 4 for more descrip-
tion). Recent analyses of multiple cohorts have highlighted the
role of timing of sensitization and other risk factors, and ongoing
efforts are focused on how best to target risk and potentially
prevent the progression from intermittent wheeze to persistent
asthma.137,143–147
Respiratory symptoms during early childhood often change, so
when asthma is suspected or diagnosed, regular reassessment of
symptoms (eg, every 2–3 months) is important.
For diagnosis, younger children present additional challenges for
treatment. Although the goals of managing asthma in young chil-
dren are similar to those for older children and adults, maintaining
normal activity and play levels is particularly important for social
and physical development. Recognizing and incorporating the goals
of parents and caregiver also is important.2
Young children might require different considerations as to what
medications to use and how to deliver them. There are no studies
that directly compare different drug delivery systems in this age
group. The following recommendations are based on published
current guidance and the authors’ expert opinion.
First, the initial treatment of any wheezing episode is an inhaled
SABA, administered every 4–6 hours as needed for at least 1 day
until symptoms disappear. This treatment should be adminis-
tered regardless of whether the diagnosis of asthma has beenmade2
(Fig 2B).
Second, choices for preschool children with intermittent asthma
symptoms or episodic virus-induced wheezing and a positive mAPI
score include pre-emptive high-dose episodic ICS or LTRA. These
approaches can lessen intermittent symptoms of asthma and de-
crease cumulative corticosteroid exposure.45,135 Intermittent ICS also
can lessen the risk of severe exacerbations.29
Seven days of budesonide inhalation suspension (1 mg twice
daily) or montelukast (4 mg daily) given in addition to albuterol at
the ﬁrst sign of symptoms associated with respiratory tract illness
signiﬁcantly improved indicators of severe acute illness (eg, trouble
breathing, decrease in activities) compared with conventional
therapy in young children (1–5 years old) with moderate-to-
severe intermittent wheezing.148 Positive response to treatment was
associated with a history of an asthma exacerbation requiring OCS
in the prior year and/or a positive mAPI score.58 Neither treat-
ment affected other outcomemeasures (eg, OCS rescue, urgent care
visits, ED visits, hospitalizations).
The effect of intermittent vs conventional daily treatment with
budesonide inhalation suspension was subsequently studied in 278
children (12–53months old) with recurrent wheezing, positivemAPI
score, and at least 1 asthma or wheezing exacerbation in the prior
year and infrequent impairment.149 The children received treat-
ment over the course of a year: intermittent treatment, 1 mg of
budesonide nebulization twice daily for 7 days, starting early during
a predeﬁned respiratory tract illness, vs daily budesonide nebuli-
zation treatment using 0.5 mg nightly throughout the year. The
treatments were comparable in decreasing the frequency and se-
verity of exacerbations, but the intermittent protocol decreased total
exposure to budesonide by approximately 100 mg over the 1-year
period.149
Third, the ﬁndings of differential clinical beneﬁt to treatment in
young children have contributed to the recent emphasis on a
phenotype-based approach to managing preschool children with
recurrent wheezing. (Fig 5).45,135 In addition to mAPI status and
wheezing severity, parental history of asthma and eczema can be
assessed to identify potential involvement of a T2 inﬂammatory
pathway and help with decision making.29,140,150
For children with a positive mAPI score and uncontrolled respi-
ratory symptoms or frequent wheezing episodes (≥3/season) or those
with a family or personal history of atopy and/or aeroallergen sen-
sitization, a trial of daily low-dose ICS is recommended (Fig 5; see
Table 4 for ICS dosing), with evaluation of response to therapy after
2 to 3 months or sooner if necessary.2,29,45,135
Fourth, for preschool children who have recurrent severe wheez-
ing with lower respiratory tract illnesses, a therapeutic trial of
azithromycin early in the course of the illness could be helpful to
prevent symptom progression to the level requiring OCS45,135,151
(Fig 5). It is notable that this therapy was comparably effective in
children with positive and negative mAPI scores. If wheezing is de-
creasedwith a trial of azithromycin, then this approach is reasonable
and can be considered for subsequent illnesses in these children.2,45
Fifth, choosing an inhalation device to deliver ICSswith orwithout
bronchodilators should be based on the child’s age, capability, and
family preference. There are advantages and disadvantages with
nebulizers and pressurizedmetered-dose inhalers and valved holding
chambers with facemask for children younger than 4 years and
mouthpiece for those who are older49 (Table 5). Nebulizer and
metered-dose inhaler delivery have been used in clinical trials dem-
onstrating eﬃcacy of ICS in young children.
Sixth, frequent reassessment (1–3 months) is necessary because
asthma-like symptoms remit in some young children. Recommen-
dations are lacking for the frequency of reassessing management,
but hospitalizations, urgent care visits, and need for short courses
of OCSs should prompt an early follow-up. The 5-item TRACK ques-
tionnaire can help parents evaluate the level of control of respiratory
symptoms in their young child40,41 (eTable 2). A change in score of
at least 10 points suggests the need to re-evaluate the child’s
treatment.
Seventh, the parents and caregiver should be included in treat-
ment decisions; their involvement is critical formanagement success.
They need to understand the relative beneﬁts and risks of the treat-
ments and the importance of maintaining normal sleep and activity
levels for their child’s physical and social development.2,3
Parents can have concerns about the effects of ICS on growth and
should be reassured that the beneﬁts of treatment outweigh the
risks. Poorly controlled asthma adversely affects growth and adult
height. For more information, the reader is directed to current
guidelines.2,3
Referral to a pediatric asthma specialist is suggested at the lower
steps and strongly recommended at the higher steps before ad-
justing therapy.
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Figure 5. Strategies to evaluate and treat recurrent wheezing in young children.45,135 ED, emergency department; ICS, inhaled corticosteroid; LRTI, lower respiratory tract
infection; LTRA, leukotriene receptor antagonist; mAPI, modiﬁed Asthma Predictive Index; OCS, oral corticosteroid; Sx, symptoms.
Table 5
Considerations When Using Aerosol Delivery Devices in Children
Nebulizer pMDI + spacer DPI
General considerations47
Advantages patient coordination not required portable and compact portable and compact
effective with tidal breathing can be used quickly can be used quickly
potential to administer multiple
medications
possible lower cost no drug preparation
dose modiﬁcation possible no drug preparation breath actuated, requires less
patient coordination
MDI with breath-actuated
mouthpiece requires less patient
coordination
no need for propellant
Disadvantages lack of portability need to coordinate actuation and
inhalation
loss of dose if patient exhales back
into device
lengthy treatment times potential for high pharyngeal
deposition
potential for high pharyngeal
depositionsome medications might not be
available in appropriate
formulation
variability of performance
eﬃciency
facemask must ﬁt properly—unless
the nebulizer mist is entrained,
the therapeutic effect might not
be adequate
less eﬃcient
more expensive
Recommendations for children and
infants (courtesy Anne M.
Fitzpatrick, PhD)
Infants (<2 y old) most reliable, easy to use masks required, unpredictable never appropriate
Preschool (2–5 y old) effective and eﬃcient with breath-
enhanced mouthpiece
can work, requires practice not appropriate
results less predictable
School age (>5 y old) effective and eﬃcient with breath-
enhanced mouthpiece
effective, requires practice easy to use
could be less predictable deposition varies by device
Abbreviations: DPI, dry powder inhaler; pMDI, pressurized metered-dose inhaler.
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Step-up: intermittent asthma to mild persistent asthma (GINA step 1
to step 2)
Daily low-dose ICS is the preferred initial treatment for persis-
tent asthma in most young children (<5 years old) with asthma
symptoms and recurrent wheezing episodes for whom step 2 treat-
ment is warranted.2,3 However, there is considerable phenotypic
heterogeneity in symptoms and response to treatment in this age
group, and some children might respond well to regular treat-
ment with a LTRA or to as-needed treatment with an ICS (given at
the same time as as-needed albuterol).45,135 This was demon-
strated in the Individualized Therapy for Asthma in Toddlers
(INFANT) study (eTable 3), which evaluated these 3 approaches in
preschool children (12–59 months old) using a crossover design of
16 weeks for each.29 Outcomes were assessed in relation to OCS use
in the previous year, sex, and evidence of aeroallergen sensitivity
at baseline. Overall, daily ICS was associated with more asthma
control days and less risk of exacerbation than the other 2 thera-
pies, and the likelihood of positive outcomes for this approach
increasedwith indicators of T2 type inﬂammation (aeroallergen sen-
sitization and/or blood eosinophil level ≥300 μL). However, other
children had a best response to LTRA or to as-needed ICS.29,45 Reviews
of the use of ICS in young children with recurrent wheezing support
the role of atopy and family history of atopy as predictors of a fa-
vorable response.45,58,135,147
Treatment was further differentiated according to the nature of
the child’s wheezing episodes—intermittent ICS (given at the same
time as as-needed SABA) provided clinical beneﬁt for some chil-
dren with episodic wheeze, whereas children with multi-trigger
wheeze were more likely to do well on daily ICS.29
The selection of medication and how it is administered in this
age group should be carefully reviewed and monitored. There is no
universal approach. More data are needed on treatment decision
making in relation to phenotypic characteristics and likelihood of
beneﬁt.
Other Options
Young children with frequent viral-induced wheezing but who
have asthma symptoms between infections might be able to use
the episodic high-dose ICS approach described in the previous
section (step 1) to prevent exacerbations.2,58,148 High-dose budesonide
(1 mg twice daily) given for 7 days starting at the outset of a pre-
deﬁned respiratory tract illness showed similar eﬃcacy to daily low-
dose budesonide (0.5 mg given once daily in the evening) in
decreasing the frequency of exacerbations requiring OCS, but over
time decreased corticosteroid exposure.149
The use of daily ICS could be particularly important for young
children to lower risk, because it is clear that:
1. Chronic airway inﬂammation exists even in patients with in-
frequent symptoms and in newly diagnosed patients.2
2. Treatment with regular low-dose ICS can lessen asthma-related
exacerbations, including severe events requiring hospitalization.2
How much ICS is necessary to counter the adverse effects of
ongoing respiratory inﬂammation is not clear. Although the eﬃ-
cacy of using episodic ICS was demonstrated in 2 1-year clinical
trials, that treatment was given speciﬁcally in response to the
onset of a respiratory tract illness, and not year-round on a regular
basis.148,149 Treatment of the young child should be individualized
according to presentation with regard to the frequency and sever-
ity of symptoms and parental perception. Long-term regular and
consistent follow-up is critical in this age group. Early, frequent,
and severe symptoms should be a red ﬂag for closer supervision
and follow-up.
Step-up: mild persistent asthma to moderate persistent asthma
(GINA step 2 to step 3)
The preferred option for the young child needing a step-up from
mild persistent to moderate asthma is to double the initial low-
dose ICS2 (Table 4).
Although data are very limited, the option of increasing the
ICS dose in a young child (or infant) is supported by a few older
studies that have shown small improvements in some outcomes
for some patients by increasing the dose of FP delivered by the
BabyHALER Spacer Device (GlaxoSmithKline, Mississauga, Ontario,
Canada)152 or budesonide inhalation suspension153; other studies
have not shown similar incremental increases in eﬃcacy with
dose.154 The differences in achieving symptom control in these
studies suggest that dose requirements for young children should
be individually and carefully titrated. Further comparisons are
diﬃcult because of different age groups and study design.
Other Options
The addition of LTRA to low-dose ICS is an alternative to in-
creasing the dose of ICS.2,3 There are no published data supporting
this approach in this age group; its consideration is based on the
approval of LTRA for this age group and extrapolation from studies,
including the BADGER study in older children69 (eTable 3).
Low-dose ICS plus LABA is not recommended as step 3 therapy
for children younger than 5 years.2,3 However, the prospective eval-
uation of adding salmeterol to FP in children with asthma (described
earlier; also see eTable 3) included some patients as young as 4
years.66 A sub-analysis of the 4- to 6-year-old group, like the data
overall, showed no between-treatment differences.
Patient Proﬁle
This proﬁle concerns the child no older than 5 years with wheez-
ing (with or without coughing) more than twice a week or who
wakes up due to wheezing at least once a month and/or has a
TRACK score at least 10 points lower than previously deter-
mined (eTable 2) or at least 2 exacerbations requiring OCS, urgent
care, or hospitalizations in the past year despite using as-
needed (intermittent) ICS or LTRA (given at same time as as-
needed SABA).
The child should be assessed for nonadherence with the man-
agement plan, potential comorbidities, and other factors that
might negatively affect response to therapy including parent and/
or caregiver understanding of asthma and its management
(Table 3).
Patient Proﬁle
This proﬁle concerns the child no older than 5 years who
remains symptomatic (eg, wheezing with or without coughing
more than twice a week or who wakes up from wheezing
≥1 time a month) after 3 months of treatment with a daily
low-dose ICS, who has a TRACK score that has decreased at
least 10 points (eTable 2), and/or has experienced at least 2
exacerbations requiring OCS or ED visit or hospitalization in
the past year.
Before stepping up therapy, the young child should be as-
sessed for nonadherence, potential comorbidities, and other
factors that might negatively affect response to therapy, as
described in the proﬁle for the initial step-up, GINA step 1 to
step 2.
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Step-up: moderate persistent asthma to severe asthma (GINA step 3
to step 4)
Treating preschool children with uncontrolled moderate-to-
severe asthma presents clinical challenges. These children frequently
present with more severe intermittent and episodic disease than
with continuous or persistent severe illness.8 Furthermore, GINA step
4 care has not been studied in clinical trials in young children with
asthma. The absence of credible data to support speciﬁc GINA step
4 treatment in preschool children presents a major clinical chal-
lenge. As such, recommendations are extrapolated from those used
for children 6 to 11 years of age, while recognizing the limitation.
Many illnesses masquerade as asthma in the young child with
recurrent wheezing and respiratory symptoms (Table 2), so it is par-
amount that great effort is extended to ensure that asthma is not
misdiagnosed in this age group, which is further complicated by
the diﬃculty of obtaining useful lung function in young children
in the clinical setting.
Increasing the ICS dose for at least 3 months could help to gain
better asthma control in the young child.2 For children using a
metered-dose inhaler with spacer and facemask, a trial of nebu-
lized budesonide might be considered.152 Once control is gained,
it might be possible to lower the ICS dose with or without adding
other treatment options (eg, LTRA). Optimizing ICS use is essen-
tial to ensure that the lowest dose is used (Table 4) and that
inappropriate dosing is avoided; adverse steroid effects can be par-
ticularly detrimental at this age.48,155
The addition of a LTRA to medium-dose ICS could be helpful. The
LTRA montelukast is indicated for children with asthma as young
as 12months.156 A trial of montelukast withmedium-dose ICSmight
be an option for some patients.
Although FP plus salmeterol (100 μg plus 50 μg) dry powder is
approved for 4 years of age,157 other doses and ICS plus LABA com-
bination agents are not approved for use in this age group. FP plus
salmeterol in ﬁxed combination (with FP daily doses of 200 and
500 μg divided twice daily) comparedwith FPmonotherapy has been
studied in children 4 to 11 years old (N = 6,208) as described earlier66
(eTable 3). Approximately one-third of children were 4 to 6 years
of age. The risk of serious asthma-related events was comparable
for the combination therapy and the monotherapy, with inci-
dences of 0.9% and 0.7%, respectively, and no asthma-related deaths
or intubations in any group.66 The safety results are similar to data
reported for adults and adolescents67 and provide some reassur-
ance of the safety of LABAs used in ﬁxed combination with ICS in
the treatment of persistent asthma in children as young as 4 years.
Using a ﬁxed-dose combination might provide some added ﬂexi-
bility for young children with diﬃcult-to-control disease (step 4 and
beyond). Prospective studies are needed to conﬁrm the clinical value
of this approach in younger children.
Discussion
Children and adolescents have different needs than adults when
it comes to identifying andmanaging poorly controlled asthma. The
patient proﬁles presented in the Pediatric Asthma Yardstick (and
summarized in Fig 1) are based on current guidelines and clinical
experience, but gaps exist.
• Managing asthma in children is evolving in relation to hetero-
geneity of response. Treating by phenotype is becoming the new
care model.
Althoughmonotherapy with low-dose ICS remains the initial rec-
ommendation for a sustained step-up for most children diagnosed
with mild persistent asthma in the United States, intermittent use
of ICS has been suggested as an alternative for some.2 Similarly, al-
though the preferred step-up from mild persistent asthma to
moderate persistent asthma is adding a LABA to an ICS, some chil-
dren do better with increasing the dose of ICS or adding a LTRA.2
Predictors of a positive response to either step-up likely reﬂect an
interplay among genetic background, immunopathology, and early
environmental exposures.16,29,47,58,69,70,135 Studies are ongoing to better
understand the differences for determining potential “best”
treatments.
However, it should not be inferred that a particular therapy will
be ineffective if the child does not meet speciﬁc characteristic(s);
rather, if 1 treatment within a given step is not effective, another
therapy within the step should be tried before stepping up to a
higher level.29,44,54,69,70,120,149
By limiting therapies to those who are more likely to respond,
treating by phenotype should allow better personalization of care,
leading to improved clinical outcomes, fewer adverse effects, and,
possibly, lower costs.
• For children with persistent asthma who can perform spirom-
etry, monitoring lung function on at least a yearly basis is
recommended to identify those at risk for adverse adult out-
comes, including chronic irreversible loss in pulmonary function.
Most children with asthma show abnormal patterns of lung
growth and have evidence of diminished lung growth by early
adulthood.10,14 More data are needed regarding whether earlier iden-
tiﬁcation of the child with asthma andmore aggressive and targeted
intervention, including after spirometry as early as possible and then
over the long-term as part of risk assessment, might help slow the
decline in lung function and deterioration into ﬁxed airway ob-
struction. More detail is provided in eCommentary 1.
• Strategies to assist in identifying the child with a loss of, or
ongoing poor, asthma control are needed. Electronic monitor-
ing could be helpful.
Continued symptoms, night-time sleep disturbance, and exac-
erbations despite optimal medication use suggest a need to re-
evaluate the child’s treatment plan. Most strategies rely to some
extent on self-reporting using different tools available for pa-
tients, with various degrees of accuracy. Despite increasing
symptoms, the patient (or caregiver) might not recognize the need
for attention. Electronic monitoring of SABA rescue has been pro-
posed as another way to obtain real-time feedback for intervention,
possibly helping to identify the onset of uncontrolled asthma, even
when the child (or parent or caregiver) does not recognize the in-
crease in symptoms.158–161
What is meant by good asthma control and how to achieve it
require regular discussion and agreement among the child patient,
family, and clinician. The Pediatric Asthma Yardstick provides a prac-
Patient Proﬁle
This proﬁle concerns the young child who is symptomatic (eg,
wheezing with or without coughing throughout most days or
who wakes up due to wheezing ≥1 time a week) and/or who has
a decrease in TRACK score of at least 10 points (eTable 2) after
3months of treatment formoderate persistent asthma (ie, double
low-dose ICS with or without LTRA) and/or whose daily activ-
ity is limited by symptoms and/or who has experienced at least
3 exacerbations requiring OCS or ED visit or hospitalization in
the past year.
Before stepping up therapy, the patient should be assessed for
nonadherence, potential comorbidities, and other factors that
might negatively affect response to therapy, as described in the
proﬁle for the initial step-up, GINA step 1 to step 2.
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tical resource to help manage these patients who bear a signiﬁcant
burden of the disease and whose care challenges current under-
standing of asthma because of its variable presentation within
individuals and within the population of children affected. Improv-
ing asthma management for children can lead to better outcomes
as they become adults.
Supplementary Data
Supplementary data related to this article can be found at https://
doi.org/10.1016/j.anai.2018.04.002.
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eCommentary 1
Lung Health with Age and Impact on Asthma Therapy in Children
The physiologic characteristics of the healthy human lung change
with age, and these changes signiﬁcantly affect the phenotypic fea-
tures of asthma and response to treatment. Lung function volume
indicators measured by spirometric change during normal devel-
opment (summarized in Table 1). The FEV1 and forced vital capacity
increase during childhood, peak by 20 to 25 years of age, and then
decrease during adulthood.e1 However, 75% of children with asthma
have abnormal lung growth patterns.e2 With severe disease, chronic
airﬂow limitation is common and is deﬁned by a ratio of FEV1 to
forced vital capacity lower than normal.e3 Airﬂow limitation, when
identiﬁed at school age, commonly persists through adolescence
and into adulthood.e4,e5 Although most children with asthma have
normal lung function between exacerbations, in childrenwith severe
asthma and airﬂow limitation, even treatment with a systemic cor-
ticosteroid might not improve FEV1 when given at a time of disease
stability.e6 No current therapy, including anti-leukotrienes, corti-
costeroids, or biological agents, has been shown to prevent or
interrupt the enhanced age-dependent decrease in FEV1 that is a
feature of childhood asthma.
Forced expiratory ﬂow between 25% and 75% has been sug-
gested as a possibly more sensitive predictor of lack of asthma
control compared with FEV1. However, although it is a measure as-
sociated with symptoms, its utility as a predictor of loss of control
or improved control is limited.e7
Bronchial hyperresponsiveness (BHR), the tendency of the airways
to constrict in response to a range of provocative stimuli, is a car-
dinal feature of asthma. BHR decreases with age in healthy children.e8
In children with asthma, BHR likewise decreases signiﬁcantly across
puberty, more so in boys than in girls.e9 Increased bronchodilator
responsiveness (BDR), the change in FEV1 from baseline after
albuterol, is an important feature of asthma. Although a 12% in-
crease in FEV1 is generally considered a positive test result, many
children, particularly those with normal pre-albuterol FEV1, do not
demonstrate BDR. BDR decreases with age, is greater in severe than
in nonsevere asthma, and loss of BDR with maturation strongly cor-
relates with the development of chronic airﬂow limitation.e3
Other age-dependent changes in respiratory system physiolo-
gy can affect response to asthma treatment and should be considered
before a long-term treatment change. Static lung compliance, mea-
sured in the absence of ﬂow, is relatively stable with age.e10 In
contrast, chest wall compliance is relatively high in preschool
children and decreases signiﬁcantly with maturation.e11 The fact
that lung compliance is lower than chest wall compliance in young
children contributes to chest wall distortion manifested by retrac-
tions with episodes of wheeze. Dynamic lung compliance, measured
during tidal breathing, decreases when measured at rapid breath-
ing frequencies and is a valid test of small airway obstruction in
patients with asthma.e12 Speciﬁc respiratory resistance, airway
resistance during tidal breathing normalized for functional resid-
ual capacity, increases with age, and the trajectory of this increase
is greater in school-age childrenwith asthma comparedwith healthy
children.e13 Although resistance of the peripheral airways contrib-
utes relatively little to the overall ﬂow resistance of the lung, the
peripheral airways account for a large surface area involved in
respiratory gas exchange. Peripheral airway resistance decreases
from preschool to school agee14 and is increased in adults with
asthma.e15
The distribution of ventilation in the developing lung is gov-
erned in part by ﬂow resistance of the branching airways and
regional elastic recoil forces. In asthma the distribution of ﬂow re-
sistance in the respiratory tree is heterogeneous and promotes
maldistribution of ventilation. Large nonventilated lung regions are
visible as ventilation defects on inhaled hyperpolarized helium-3
magnetic resonance images and are common in asthma.e16 Chil-
dren with severe asthma have greater nonventilated and poorly
ventilated lung volume compartments compared with children with
nonsevere asthma. Ventilation heterogeneity in the peripheral
airways also can be measured with forced oscillometry as the dif-
ference in total respiratory resistance measured at 5 Hz minus large
airway resistance at 20 Hz. Children with asthma and poor symptom
control have greater ventilation heterogeneity measured with this
technique compared with children with controlled asthma.e17 Mul-
tiple breath nitrogen washout is a third method that can be used
tomeasure ventilation heterogeneity using the lung clearance index,
a metric that is abnormally high in children with asthma even with
normal lung function and few symptoms.e18
Age-dependent considerations for medication delivery devices The
physiologic features of the developing respiratory system deter-
mine the optimal selection of delivery devices to administer inhaled
medication. Deposition of inhaled particles including medica-
tions in the distal lung is affected by inspiratory ﬂow velocity and
particle size.e19 Young preschool children are at a particular disad-
vantage because they might not be able to follow instructions to
take a deep, slow breath so that relatively more medication affects
the oropharynx.e20 For this reason jet nebulizers are commonly used
in this age group, with the relative advantages of being effective with
tidal breathing, not requiring a tight seal, and being used conﬁ-
dently in the face of respiratory distress.e19,e20 Disadvantages of
nebulized medications include lack of portability, prolonged ad-
ministration time, and generation of relatively large medication
droplets by standard nebulizers for home use, thereby decreasing
deposition in the peripheral lung zones.e19
Metered-dose inhalers with hydroﬂuoroalkane propellant are
widely used to administer corticosteroids in suspension or in so-
lution. A signiﬁcant advantage of solution formulations is the
ultraﬁne particle size with enhanced penetrability compared with
ICS in suspension. In the latter, the particle size is relatively coarse,
resulting in greater deposition in the oropharynx.e19 However, cur-
rently there are no comparative clinical trials that conclusively show
greater beneﬁt of ﬁne-particle vs coarse-particle ICS in attaining
asthma control in children. Another important factor when select-
ing therapy is the biological potency of the corticosteroid molecule,
which varies considerably among available products. Table 4 pres-
ents relative dosing thresholds for children at different age levels,
which are based not on biological potency but on reported adverse
effects proﬁles for consideration.
The use of a mask and spacers or spacers alone (also termed
valved holding chambers) to enhance the delivery of ICS is strongly
advised in most treatment guidelines for children.e20,e21 The selec-
tion of a mask with a spacer or a spacer with a mouthpiece is based
on the age of the child, developmental level, and conﬁdence of the
parent. Newer formulations including dry powder inhalers to deliver
ICS and reliever therapies are available for use in children. The ad-
vantage of these systems is ease of use and portability, but clinicians
should be aware that the particle deposition from these devices is
dependent on a relatively higher inspiratory ﬂow velocity.e19 Thus,
they might not be suitable for young children who cannot gener-
ate the necessary inspiratory ﬂow or for children who have diﬃculty
following instructions. In addition, and especially for younger chil-
dren, parent and caregiver understanding of the inhalation device
and how it should be used is important for successful treatment.e20
eCommentary 2
Methods
The authors reviewed the current evidence for various FDA-
approved treatment options identiﬁed by the most recent
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guidelinese20,e21 according to age (adolescence, 12–18 years old;
school age, 5–11 years old; young, <5 years old) and the type of step-
up (mild persistent asthma to moderate persistent asthma, GINA
step 2 to step 3; moderate persistent asthma to severe persistent
asthma, GINA step 3 to steps 4 and 5). Newer data and potential
treatment options not yet described in the guidelines also were
evaluated when appropriate. The evidence was not graded, except
as graded for the guidance documents. For the initial draft, the
authors worked on sections as follows: GINA step 1 to step 2: Dr
Szeﬂer and Dr Bacharier; GINA step 2 to step 3: Dr Murphy and Dr
Jackson; childrenwith severe and diﬃcult-to-treat disease: Dr Zeiger
and Dr Phipatanakul; and lung development and implications for
drug delivery: Dr Teague. Patient proﬁles were created as practi-
cal points of reference for the reader, and the associated ﬂow
diagrams (Fig 1) provide the authors’ concept for a “best practice
summary” of the available strategies for increasing and/or modi-
fying therapy according to the child’s asthma severity and level of
disease control. All authors reviewed and provided appropriate re-
visions to the manuscript in development, and all gave written
approval to the ﬁnal document. It is anticipated that, like the guide-
lines, the Pediatric Asthma Yardstick will be updated on a regular
basis according to new research ﬁndings.
eCommentary 3
Identifying Biomarkers for Omalizumab Success
The EXTRA trial, a prospective, multicenter, randomized, double-
blinded, placebo-controlled study that included adolescents and
adults with uncontrolled severe persistent asthma, reported sig-
niﬁcant decreases in exacerbation rates with omalizumab treatment
compared with placebo (incidence rate: omalizumab 0.66; placebo
0.88).e22 Post hoc analyses divided the 850 enrolled subjects into
groups with high and low T-helper cell type 2 (TH2), with the latter
further deﬁned by the baseline levels of several biomarkers asso-
ciated with TH2-driven inﬂammation, including blood eosinophil
count of at least 260/μL and FeNO of at least 24 ppb.e23 After 48
weeks of treatment, the high TH2 group demonstrated signiﬁcant
decreases of exacerbations compared with the low TH2 group (FeNO
53% vs 16%; eosinophils 32% vs 9%), supporting the use of these
biomarkers for predicting response.
Other attempts to delineate potential patient characteristics for
successful outcomes with omalizumab included studies of comorbid
conditions that can exacerbate allergic asthma, such as concomi-
tant rhinosinusitis and nasal polyps. Rhinovirus (RV) and serum IgE
are associatedwith acute asthma exacerbation severity in children,e24
and treatment with omalizumab has been shown to lessen the se-
verity of RV-induced exacerbationse25 and to decrease the duration
of RV infections, viral shedding, and risk of RV illnesses.e26 Ex vivo
analysis of peripheral bloodmononuclear cells from a subset of chil-
dren in the pre-seasonal omalizumab studye27 showed that
omalizumab enhanced the interferon-α response to RV. Children
treated with omalizumab who had greater increases in interferon-α
levels had fewer exacerbations (odds ratio 0.14; 95% CI 0.01–
0.88). Additional studies are needed to conﬁrm the ﬁndings.
eCommentary 4
The Asthma Predictive Index and Modiﬁed Asthma Predictive Index
The API and the mAPI are tools to help clinicians identify young
children at high risk for developing asthma.e28 The primary crite-
ria for the indices reﬂect wheezing episodes in the young child;
the secondary criteria include diagnosis or likelihood of allergic
disease.
Index Primary criteria Secondary criteria
Major (≥1) Minor (≥2)
API early frequent
“wheezer” (parent
classiﬁcation ≥3 on
1–5 scale)
parental history of
asthma
physician-diagnosed
allergic rhinitis
physician-diagnosed
atopic dermatitis
wheezing unrelated to
colds
blood eosinophils ≥4%
mAPI ≥4 wheezing
episodes/y
parental history of
asthma
allergic sensitization to
milk, egg, or peanuts
physician-diagnosed
atopic dermatitis
wheezing unrelated to
colds
allergic sensitization to
≥1 aeroallergen
blood eosinophils ≥4%
Abbreviations: API, Asthma Predictive Index; mAPI, modiﬁed Asthma Predictive Index.
The API was ﬁrst used in the Tucson Children’s Respiratory Study,
which evaluated the characteristics of a general cohort of 1,246
infants in an attempt to “predict” the occurrence of asthma at 6,
8, 11, and 13 years of age, based on questionnaire data from tod-
dlers (2–3 years old).e29–e31 The positive likelihood ratio and negative
likelihood ratio for asthma diagnosis at 6 years were 7.4 and 0.75,
respectively. Following the children showed a strong correlation
between a positive ratio and probability of future asthma at school
age and persisting beyond school age; the correlation between a
negative score and decreased probability of future asthma expres-
sion was not as substantial.e29,e30
The mAPI uses more objective criteria than the API. For example,
wheezing episodes are quantiﬁed by number rather than subjec-
tive scoring, and allergen sensitization is determined by IgE levels
or skin prick testing.e32 The diagnostic utility of the mAPI was pro-
spectively demonstrated in a high-risk asthma cohort of toddlers
(1–3 years old) for asthma diagnosis at 6, 8, and 11 years of age.e28
A positive mAPI score was associated with an increased probabil-
ity of future asthma risk, whereas a negative score was associated
with a small decrease in future asthma probability.
The API andmAPI are easily applied in the clinical setting.e28,e32,e33
A separate index developed from the mAPI, the m2API, requires 2
instead of 4 wheezing episodes in the course of a year for a posi-
tive test result, thereby shortening the wait before clinical decision
making.e28 However, them2API has shown less correlationwith future
asthma risk than the mAPI.
Regardless of instrument and outcome, subsequent clinical
decision making should involve further monitoring alone or
with the addition, or modiﬁcation, of therapy, as described in the
text.
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Assessing Asthma Control by Impairment and Risk (Adapted From National Asthma Education and Prevention Program, 2007)e21
Components of control Classiﬁcation of asthma control
Well controlled Not well controlled Very poorly controlled
A. Children ≥12 y old (and adults)
Impairment symptoms ≤2 d/wk >2 d/wk throughout day
night-time awakenings ≤2 × /mo 1–3 × /wk ≥4 × /wk
interference with normal activities none some limitation extremely limited
using SABA for symptoms (not prevention of EIB) ≤2 d/wk >2 d/wk several times daily
FEV1 or PEF >80% predicted or personal best 60–80% predicted or personal best <60% predicted or personal best
validated questionnaires
ACT ≥20 16–19 ≤15
ACQ ≤0.75 ≥1.5 N/A
ATAQ 0 1–2 3–4
Risk exacerbations requiring OCS ≤1/y ≥2/y
progressive loss of lung function long-term follow-up required
treatment-related adverse effects can vary from none to troublesome or worrisome;
intensity does not correlate with level of control but
should be considered in overall assessment of risk
B. Children 5–11 y old
Impairment symptoms ≤2 d/wk and not >1 × /d on those days >2 d/wk or multiple times on ≤2 d/wk throughout day
Night-time awakenings ≤1 × /mo ≥2 × /mo ≥2 × /wk
interference with normal activities none some limitation extremely limited
using SABA for symptoms (not prevention of EIB) ≤2 d/wk >2 d/wk several times daily
FEV1 or PEF >80% predicted or personal best 60–80% predicted or personal best <60% predicted or personal best
FEV1/FVC >80% 75–80% <75%
Validated questionnaires
cACT ≥20 13–19 ≤12
Risk exacerbations requiring OCS ≤1/y ≥2/y
progressive loss of lung function long-term follow-up required
treatment-related adverse effects can vary from none to troublesome or worrisome;
intensity does not correlate with level of control but
should be considered in overall assessment of risk
Children 0–4 y old
Impairment symptoms ≤2 d/wk >2 d/wk throughout day
nighttime awakenings ≤1 × /mo ≥1 × /mo ≥1 × /wk
interference with normal activities none some limitation extremely limited
using SABA for symptoms (not prevention of EIB) ≤2 d/wk >2 d/wk several times daily
validated questionnaires
TRACK score of 80–100 a change in TRACK score ≥10 points indicates clinically
meaningful change in respiratory or asthma control; for
children with symptoms consistent with asthma, this
should alert the health care provider to review the
child’s asthma treatment plan
Risk exacerbations requiring OCS ≤1/y 2–3/y >3/y
treatment-related adverse effects can vary from none to troublesome or worrisome;
intensity does not correlate with level of control but
should be considered in overall assessment of risk
Abbreviations: ACQ, Asthma Control Questionnaire; ACT, Asthma Control Test; ATAQ, Asthma Therapy Assessment Questionnaire for Children and Adolescents; cACT, Childhood Asthma Control Test; EIB, exercise-induced
bronchoconstriction; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; N/A, not applicable; OCS, oral corticosteroid; PEF, peak expiratory ﬂow; SABA, short-acting β2-agonist; TRACK, Test for Respiratory
and Asthma Control in Kids.
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eTable 2
Validated Asthma Control Questionnairese34,e35
Questionnaire Description Included in questionnaire Other comments
Symptom frequency Rescue therapy use Sleep disturbance Activity limitation Exacerbations
Asthma Control Test(ACT)e36,e37 ≥12 y old X X X X no overall self-rating of control included; each item
scored from 1 to 5
5 questions answered monthly maximum score 25
score <19 suggests asthma not controlled
MID 3
survey license request required for use
Childhood ACT (cACT)e38,e39 4–11 y old X no X X no overall parent and child ratings of control
included: 4 questions to child, maximum score
for each question is 3; 3 questions for parent,
maximum score for each question is 5
7 questions answered monthly
(by parent and/or child)
combined maximum score 27
score <19 suggests asthma not controlled; score
<12 suggests asthma poorly controlled
MID 2
Pediatric Asthma Therapy
Assessment Questionnaire
for Children and Adolescents
(pATAQ)e40
5–17 y old X X X X no overall parent rating of control domain scored
from 0 (no asthma control problems) to 7 (very
high rates of asthma-related health-care use)
7 questions answered monthly
(by parent or caregiver)
no MID
Asthma Control Questionnaire
(ACQ)e41–e44 and for children
(cACQ)
6–16 y old (and adults) X X X X no items measured on scale of 0–6; score is averaged
7 questions including FEV1
completed weekly; shorter
versions with symptoms only
(5 questions) or
symptoms + rescue
medication (6 questions) or
symptoms + FEV1 (6
questions) validated in
patients ≥6 y old
score ≥1.5 suggests asthma is uncontrolled; score
<0.75 suggests asthma is well controlled
trained interviewer required
for children 6–10 y old
MID 0.5
permission needed from author to usee41,e42
Test for Respiratory and
Asthma Control in Kids
(TRACK)e45,e46
≤5 y old X X X X X each item scored from 0 to 20
5 questions answered by
parents or caregivers: 3 on
monthly symptoms, 1 on
3-mo rescue medication use,
1 on exacerbations in past
year
maximum score 100
score <80 suggests possible poor control of child’s
breathing problems; ≥10-point change in score
suggests need to re-evaluate child’s treatment
MID 10
Composite Asthma Severity
Indexe47,e48
6–17 y old X X X no X maximum score 20
5 domains: daytime symptoms
and albuterol use (past
2 wk); nights with symptoms
and albuterol use (past
2 wk); lung function
(current); controller
treatment (current);
exacerbations (past 2 mo)
≥1-point change suggests change in asthma
severity; for deﬁning asthma risk levels, CASI
score ≤3 identiﬁes mild asthma (although an
increase in CASI score represents increased
severity above and below cutoff point)
predominantly a research tool
CASI is free to use; sample forms, calculator, and
other resources are publicly available at www.
asthmaseverity.org
Abbreviations: CASI, Composite Asthma Severity Index; FEV1, forced expiratory volume in 1 second; MID, minimal important difference. 579.e4
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eTable 3
Key Asthma Studies in Children and Adolescents
Study Description Subjects Outcomes Comments
Deﬁning diﬃcult-to-
control asthma
Chipps et al, 2012e49;
Epidemiology and
Natural History of
Asthma: Outcomes
and Treatment
Regimens (TENOR)
study
3-y observational multi-cohort study to
characterize natural history of diﬃcult-to-
treat asthma
data were collected every 6 mo, including
demographics, medical history,
comorbidities, asthma control, asthma-
related health care use, medication use,
lung function, IgE levels, self-reported
asthma triggers, and asthma-related QoL
N = 1,267 children 6–17 y old (497
adolescents, 13–17 y; 770
school-age children, 6–12 y)
study also included 3,489 adults
(≥18 y)
Burden of illness 3 mo before BL:
hospitalizations/ED visits: 10%/17% for adolescents, 9%/22% for
children
≥3 asthma controller medications used by >55% of
adolescents + adults and children
OCS courses (despite using ≥3 asthma controller meds) were
44% in adolescents, 53% in children
ED visits (despite using ≥3 asthma controller medications) by
19% of adolescents, 25% of children
ED visits + hospitalizations were signiﬁcantly and clinically
meaningfully higher (≈2–3-fold) in children vs
adolescents + adults regardless of BL lung function, but at
24 mo, OCS courses were signiﬁcantly higher in children
with FEV1 ≤80% predicted
Risk factors for future severe exacerbation:
recent severe exacerbation was associated with risk for future
severe asthma exacerbation at 6 mo (OR 3.08, 95% CI
2.21–4.28) for children and at 18 mo for adolescents + adults
(OR 6.33; 95% CI 4.57–8.76)
for children, other risk factors were having 3–4 allergic
triggers (OR 2.05, 95% CI 1.31–3.20), race or ethnicity
(OR 1.77, 95% CI 1.25–2.51), and having VPC asthma
(OR 1.59, 95% CI 1.14–2.23)
children who continued to have VPC asthma over 24 mo of
study had 6-fold increased risk of hospitalization, ED visit,
or OCS burst (OR 6.4, 95% CI 1.2–34.5)
regardless of age, patients with severe or
diﬃcult-to-treat asthma showed
frequent asthma exacerbations, high
rates of health care use, and substantial
asthma burden despite multiple long-
term controller medications and good
adherence
FEV1 ≤80% predicted could indicate more
severe disease for children than for
adults
continued VPC asthma despite appropriate
treatment and adherence was predictive
of clinically signiﬁcant burden of disease
subgroup cross-sectional analysis of
school-age children (6–12 y) assessed
asthma control in relation to economic
burden: greater impairment was
associated with increased direct and
indirect costs; at 12 and 24 mo, total
costs decreased for children whose
asthma control improved vs those whose
asthma remained VPC; indirect costs
accounted for ~50% of VPC costs at 12 mo
and >50% at 24 moe50
Pongracic et al,
2016e51; Asthma
Phenotypes in the
Inner City (APIC)
1-y prospective longitudinal study of children
with asthma living in 9 urban areas
at BL, children were classiﬁed as having
diﬃcult-to-control and easy-to-control
asthma based on daily therapy (FP ≥500 μg
FP ± LABA vs ≤100 μg) assigned at ≥4 visits
asthma and rhinitis were managed using
guideline-derived treatment algorithms with
assessment and medication adjustments
every 2 mo for 1 y
44 BL variables were used to compare groups
to identify the most relevant features of
diﬃcult-to-control asthma
N = 619 (6–17 y) children with
asthma receiving guideline-
based care (≥1 y)
at BL, 40.9% met criteria for
diﬃcult-to-control asthma; 37.5%
met criteria for easy-to-control
asthma; 21.6% did not meet
criteria for either
FEV1 bronchodilator responsiveness was most distinguishing
characteristic identifying children with diﬃcult-to-control
asthma; others included asthma control (using ACT or cACT),
spirometry, markers of atopy, and rhinitis
children with diﬃcult-to-control asthma showed no trend
toward improvement with guideline-based care, despite
comparable adherence to treatment between groups
ﬁndings support those of TENOR and
suggest a need for early identiﬁcation
and more aggressive treatment of
children with diﬃcult-to-control asthma
(continued on next page)
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eTable 3 (continued)
Study Description Subjects Outcomes Comments
ICS + LABA
Lemanske et al,
2010e52; Best Add-
on Therapy Giving
Effective Response
(BADGER)
48-wk R, DB, 3-treatment, 3-period, crossover
study: FP 250 μg 2 × /d (ICS step-up); FP
100 μg + LABA 50 μg 2 × /d (LABA step-up);
FP 100 μg 2 × /d + LTRA 5 or 10 mg 1 × /d
(LTRA step-up)
each treatment was given for 16 wk without
washout
N = 182 (6–17 y) who had
uncontrolled asthma while
receiving FP 100 μg 2 × /d
161 of 165 children evaluated had differential response to
treatment (P < .001)
LABA step-up was most likely to be the best response vs LTRA
step-up (relative probability 1.6, 95% CI 1.1–2.3, P = .004) vs ICS
step-up (relative probability 1.7, 95% CI 1.2–2.4, P = .002)
not all children showed best response with
LABA step-up; some did better with ICS
or LTRA
results indicate it is important to regularly
monitor and adjust each child’s asthma
therapy
possible BL predictors of response: better
asthma control and white race showed
likelihood of best response to LABA;
black race showed weaker response to
LTRA
potential predictors were assessed further
in post hoc analyses, which suggested
associations between lower lung
function and better response to LABA
step-up and increased LTE4 and
marginally better response to LTRA
step-upe53; although children without
eczema appeared to respond best to
LABA step-up, step-up for those with
eczema could reﬂect racee54
Vaessen-Verbene
et al, 2010e55
26-wk R, PG, DB study of FP 100 μg + Sal 50 μg
vs doubling FP monotherapy (200 μg); both
given 2 × /d
N = 158 (6–16 y) symptomatic on
FP 100 μg 2 × /d
FP + Sal (n = 78)
FP double (n = 80)
percentage of symptom-free days: no difference between
treatments with ≈25% increase in the 2 groups (P < .001 vs BL)
percentage of days with rescue albuterol: no difference between
treatments and decreased with both (FP/Sal, from 38% to 22%;
FP, from 35% to 20%)
lung function: no difference between treatments and no
signiﬁcant changes from BL
mean statural growth: no difference between treatments
combination provided similar clinical
eﬃcacy at half steroid dose
Stempel et al, 2016e56 26-wk, R, DB, active comparator study
evaluating safety of FP + Sal vs FP
monotherapy
N = 6208 (4–11 y) who required
daily asthma meds and had
history of asthma exacerbation(s)
in years before study; FP + Sal
(n = 3,107), FP (n = 3,101)
primary (safety): time to ﬁrst serious asthma-related event: no
difference between treatments (HR 1.28, (CI 0.73–2.27,
P = .006)
secondary (eﬃcacy):
mean percentage of rescue therapy-free days: FP + Sal 83.0%;
FP 81.9% (P = NS)
mean percentage of days with asthma controlled: FP + Sal
74.8%; FP 73.4% (P = NS)
evidenced safety of LABA when used in
combination with ICS in same inhaler
(ICS + LABA) with ﬁndings similar to
studies in adults and adolescentse57,e58
(continued on next page)
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eTable 3 (continued)
Study Description Subjects Outcomes Comments
Bisgaard et al,
2006e59; Symbicort
Maintenance and
Relief Therapy
(SMART)
12-mo, R, DB study of Bud 80 μg + Form 4.5 μg
1 × /d + additional inhalations if needed for
symptom relief (SMART), Bud 80 μg + Form
4.5 μg 1 × /d (ﬁxed combination), Bud 320 μg
1 × /d (ﬁxed-dose Bud)
N = 341 (4–11 y) with asthma
history ≥6 mo and ≥1
exacerbation in prior year and
who were using ICS at a constant
dose for ≥3 mo (200–500 μg/d)
SMART (n = 118)
ﬁxed combination (n = 117)
ﬁxed-dose Bud (n = 106)
percentage of children with exacerbation: SMART 14% vs ﬁxed
combination 38% (P < .001) vs ﬁxed-dose Bud 26% (P = NS)
children using SMART had fewer OCS days vs children in other
2 groups
SMART signiﬁcantly prolonged time to ﬁrst exacerbation vs
ﬁxed combination (P < .001) and vs ﬁxed-dose Bud (P < .02)
both combination treatments improved lung function and
decreased NT symptoms vs ﬁxed-dose Bud; other asthma
control variables (eg, control days, symptom-free days) were
comparable between groups
growth rate over the year for children in the 2 combination
treatment groups was ~1 cm greater than children using ﬁxed-
dose Bud
pediatric asthma associated with higher
incidence of exacerbations
data suggest that the SMART approach (not
approved by the FDA) might beneﬁt
some children
Tiotropium
Vogelberg et al,
2014e60
12-wk phase II, DB, PC, incomplete crossover
(3 4-wk treatment periods), dose-ranging
study of once-daily Tio Respimat (5, 2.5, and
1.25 μg) given in evening and added to
medium-dose ICS (Bud 200–400 μg or
equivalent) ± LTRA
N = 101 (6–11 y) with asthma
history ≥6 mo
Tio 5 μg (n = 76); Tio 2.5 μg
(n = 74); Tio 1.25 μg (n = 75); Pl
(n = 76)
peak FEV1 (0–3 h) response after 4 wk (primary end point,
adjusted mean differences from Pl): Tio 5 μg, 87 mL
(P = .0002); Tio 2.5 μg, 104 mL (P < .0001); Tio 1.25 μg, 75 mL
(P = .0011) with no dose-dependent response
secondary and additional eﬃcacy end points also improved with
Tio, including trough FEV1, FEV1 AUC (0–3 h), FEV1 over 3 h
after dosing, and am and pm PEF
all treatments were well tolerated with no between-treatment
differences in AEs
this was the ﬁrst study of the Tio Respimat
in children with symptomatic asthma
focus of this phase II trial was lung
function rather than full assessment of
symptom control and exacerbations
Hamelmann et al,
2016e61
48-wk DB, PC, PG study of once-daily Tio
Respimat (5 or 2.5 μg) given in evening and
added to medium-dose ICS (Bud 200–
400 μg or equivalent) ± LTRA
N = 398 (12–17 y) with asthma
history ≥3 mo and were
symptomatic at screening
Tio 5 μg (n = 134); Tio 2.5 μg
(n = 125); Pl (n = 138)
peak FEV1 (0–3 h) response after 24 wk (primary end point,
adjusted mean differences from Pl): Tio 5 μg, 174 mL (95% CI
76–272, P < .001); Tio 2.5 μg, 134 mL (95% CI 34–234, P < .01)
secondary end points at 24 wk (adjusted mean differences from
Pl):
Trough FEV1: Tio 5 μg, 117 mL (95% CI 10–223, P = .03); Tio
2.5 μg, 84 mL (95% CI −25 to 194, P = NS)
FEV1 AUC (0–3 h): Tio 5 μg, 181 mL (95% CI 88–275, P < .001);
Tio 2.5 μg, 130 mL (95% CI 34–225, P = .008)
trends for improvement in asthma control and health-related
QoL over 48-wk treatment period were observed
all treatments were well tolerated with no between-treatment
differences in AEs
Szeﬂer et al, 2017e62 12-wk DB, PC, PG study of once-daily Tio
Respimat (5 or 2.5 μg) given in evening as
add-on to background therapy (high-dose
ICS (Bud >400 μg or equivalent) + ≥1
controller med (eg, LABA ± LTRA); or
medium-dose ICS (Bud 200–400 μg or
equivalent) + ≥2 controller meds (eg,
LABA ± LTRA ± SRT)
N = 401 (4–11 y) with severe
asthma, an asthma history
≥6 mo, and who were
symptomatic at screening
Tio 5 μg (n = 130); Tio 2.5 μg
(n = 136); Pl (n = 134)
Peak FEV1(0–3h) response after 12 wk (primary end point,
adjusted mean differences from Pl): Tio 5 μg, 139 mL (95% CI
75–203 mL), P < 0.0001; Tio 2.5 μg, 34 mL (95% CI 28–99 mL),
P = NS
secondary end point at 12 wk: trough FEV1 (adjusted mean
differences from Pl): Tio 5 μg, 87 mL (95% CI 19–154, P = .01);
Tio 2.5 μg, 18 mL (95% CI −48 to 85, P = NS)
other secondary end points were similar between treatment
groups
risk of severe asthma exacerbations and episodes of asthma
worsening was lower with Tio vs Pl (HR < 1); however, this
difference was signiﬁcant only for episodes of asthma
worsening with Tio 2.5 μg vs Pl (P = .006)
all treatments were well tolerated with no between-treatment
differences in AEs
(continued on next page)
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Study Description Subjects Outcomes Comments
Omalizumab
Milgrom et al,
2001e63
28-wk R, DB, PC study of safety, steroid-
sparing effects, eﬃcacy for exacerbations of
omalizumab
omalizumab dose based on bodyweight and
initial serum IgE: 0.016 mg/kg per IgE level
(IU/mL)
treatment was added to stable BDP dose
(initial range 168–420 g/d) for 16 wk (stable-
steroid phase), decreased over 8 wk to
minimum effective dose (steroid-decrease
phase), and maintained constant for ﬁnal
4 wk
N = 334 (6–12 y) with moderate-
to-severe allergic asthma
requiring ICS
omalizumab (n = 225); Pl (n = 109)
median decrease in BDP dose from BL: omalizumab 100%, Pl
66.7% (P = .001)
percentage of patients completely stopping BDP: omalizumab
55%, Pl 39% (P = .004)
percentage of patients with exacerbation requiring doubling
BDP dose or OCS during steroid-decrease phase: omalizumab
18.2%, Pl 38.5% (P < .001)
mean number exacerbations per patient: omalizumab 0.42, Pl
2.72 (P < .001)
no serious treatment-related AEs; 5 Pl-treated patients required
hospitalization for asthma exacerbation
no signiﬁcant between-treatment
differences for asthma symptom scores,
lung function measures (am PEFR, FEV1,
FVC, FEF25-75), but other secondary
measures suggest improved asthma
control with omalizumab
percentage of patients requiring urgent,
unscheduled physician visit:
omalizumab 12.9%, Pl 30.3% (P = .001)
percentage of patients with ≥20% decrease
in am PEFR on 2 or 3 successive days:
omalizumab 6.7%, Pl 17.4% (P = .002)
percentage of patients with awakenings
requiring rescue medications on 2 or 3
successive nights: omalizumab 11.6%, Pl
21.1% (P = .002)
subsequent 24-wk OL study in which all
subjects received omalizumab + their
other asthma medications showed trends
similar to core studye64
Lanier et al, 2009e65 52-wk R, DB, PC study of omalizumab (75–
375 mg SC q2 or q4) including 24-wk ﬁxed-
steroid phase followed by 28-wk adjustable-
steroid phase
N = 627 (6– < 12 y) with perennial
allergen sensitivity and history of
asthma exacerbations and
symptoms despite at least
medium-dose ICS
omalizumab (n = 421); Pl (n = 206)
rate of clinically signiﬁcant exacerbations (ie, worsening
symptoms requiring doubling BL ICS dose and/or OCS) over
ﬁxed-steroid phase: omalizumab 0.45, Pl 0.64 (P = .007; rate
ratio 0.69)
over 52 wk, exacerbation rate with omalizumab was decreased
by 43% vs Pl (P < .001) and signiﬁcantly decreased severe
exacerbations
no between-treatment differences in overall incidence of AEs
Kulus et al, 2010e66 52-wk R, DB, PC study of omalizumab (75–
375 mg SC q2 or q4) including 24-wk ﬁxed-
steroid phase followed by 28-wk adjustable-
steroid phase
N = 246 (6– < 12 y) with perennial
allergen sensitivity and history of
asthma exacerbations and
symptoms despite using ICS (FP
≥500 μg/d or equivalent) + LABA;
omalizumab (n = 166); Pl (n = 80)
rate of clinically signiﬁcant exacerbations (ie, worsening
symptoms requiring doubling BL ICS dose and/or OCS) over
ﬁxed-steroid phase: omalizumab 0.42, Pl 0.63 (P = .047; rate
ratio 0.662)
over 52 wk, exacerbation rate with omalizumab was decreased
by 50% vs Pl (P < .001)
no between-treatment differences in overall incidence of AEs
Busse et al, 2011e67;
Inner City Anti-IgE
Therapy for Asthma
(ICATA) study
60-wk R, DB, PC, PG study of omalizumab (75–
375 mg SC q2 or q4)
N = 419 inner city children and
adolescents or young adults (6–
20 y) with persistent allergic
asthma; subjects using controller
medications required to have
evidence of persistent symptoms
or evidence of uncontrolled
asthma in prior year, those not
receiving controller meds were
required to have persistent
symptoms and evidence of
uncontrolled disease
omalizumab (n = 208), Pl (n = 211)
omalizumab decreased symptom days per 2-wk interval
(primary end point) of 1.04 (95% CI 0.46–1.62) and decreased
percentage of subjects with exacerbations (from 10.2% to 6.1%)
effects of omalizumab were evident in
seasonal patterns of asthma symptoms
and exacerbations
exacerbations during fall and spring vs
summer (respectively): Pl 9.0% and 8.1%,
vs 4.6% (P < .001); omalizumab 4.3% and
4.2% vs 3.3% (P = NS); difference between
treatments was signiﬁcant (P < .001)
(continued on next page)
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Study Description Subjects Outcomes Comments
Teach et al, 2015e27;
The Preventive
Omalizumab or
Step-up Therapy for
Fall Exacerbations
(PROSE) study
3-arm, R, DB, DPC study of effect of
omalizumab vs Pl and vs ICS boost (doubling
ICS dose) on fall asthma exacerbations rates
when treatment was initiated 4–6 wk before
return to school
N = 513 inner city children (6–17
y) with allergic asthma, asthma
symptoms for ≥1 y, using FP
≥200 μg/d (or equivalent), and ≥1
recent exacerbation
for 318 children using FP
200– < 500 μg/d: omalizumab
(n = 133), ICS boost (n = 138), Pl
(n = 47)
for 195 children using FP ≥500 μg/
d: omalizumab (n = 145), Pl
(n = 50)
fall exacerbation rate was signiﬁcantly lower for omalizumab vs
Pl (11.3% vs 21.0%; OR 0.48, 95% CI 0.25–0.92), but not for
omalizumab vs ICS boost (8.4% vs 11.1%; OR 0.73, 95% CI 0.33–
1.64)
exacerbation rate was signiﬁcantly lower for omalizumab vs Pl
and vs ICS boost in subgroup analysis of children who had
exacerbation during run-in: omalizumab vs Pl 6.4% vs 36.3%
(OR 0.12, 95% CI 0.02–0.64); omalizumab vs ICS boost 2.0% vs
27.8% (OR 0.05, 95% CI 0.002–0.98)
omalizumab signiﬁcantly decreased asthma symptoms days in
2-wk intervals vs Pl but not vs ICS boost
omalizumab was associated with a trend toward lower odds of
respiratory virus-associated exacerbation (OR 0.52, 95% CI
0.24–1.13), which was statistically signiﬁcant for children with
more severe asthma (OR 0.35, 95% CI 0.15–0.85)
omalizumab improved IFN-α responses to rhinovirus, and
within the omalizumab group, greater IFN-α increases were
associated with fewer exacerbations (OR 0.14, 95% CI 0.01–
0.88)
targeted seasonal treatment could help in
management of high-risk children; the
cost would be lower than a full year of
treatment if appropriate patients could
be identiﬁed; more data are needed for
conﬁrmation
Young children
Fitzpatrick et al,
2016e68; The
Individualized
Therapy for Asthma
in Toddlers
(INFANT) study
R, DB, DD, crossover study of 3 16-wk
treatment periods: daily ICS, daily LTRA, and
as-needed ICS coadministered with albuterol
N = 300 (12–59 mo) with asthma
requiring daily controller
medication (step 2 care)
74% of children with analyzable data (170 of 230) had a
differential response to treatment, with the probability of best
response highest for daily ICS
response to daily ICS was predicted by aeroallergen
sensitization but not by exacerbation history or sex; in
children with aeroallergen sensitization and blood eosinophil
count ≥300/mL (suggesting T2 phenotype), daily ICS use was
associated with more asthma control days and fewer
exacerbations vs other treatments
results suggest (1) daily low-dose ICS is the
most effective treatment for most young
children with asthma symptoms and
recurrent wheezing episodes who
require controller medication; (2) there
is potential for phenotype-directed
asthma care for younger children, but
more study is warranted to better
identify predictors; (3) evidence of a T2
phenotype is associated with children
who do best with daily ICS
Abbreviations: ACT, Asthma Control Test; AE, adverse event; AUC, area under the curve; BDP, ??; BL, baseline; Bud, budesonide; cACT, Childhood Asthma Control Test; CI, conﬁdence interval; DB, double-blinded; DPC, double
placebo-controlled; ED, emergency department; FDA, Food and Drug Administration; FEF25-75, forced expiratory ﬂow between 25% and 75%; FEV1, forced expiratory volume in 1 second; Form, formoterol; FP, ﬂuticasone pro-
pionate; HR, hazard ratio; Hx, history; ICS, inhaled corticosteroid; IFN-α, interferon-α; IgE, immunoglobulin E; LABA, long-acting β-agonist; LTE4, leukotriene E4; LTRA, leukotriene receptor antagonist; med, medication; NS, not
signiﬁcant; NT, night-time; OCS, oral corticosteroid; OL, ??; OR, odds ratio; PC, placebo-controlled; PEFR, peak expiratory ﬂow rate; PG, parallel group; Pl, placebo; q2, every 2 weeks; q4, every 4 weeks; QoL, quality of life; R,
randomized; Sal, salmeterol; SC, subcutaneously; SRT, sustained release theophylline; Sx, symptoms; Tio, tiotropium; Tx, treatment; VPC, very poorly controlled.
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